AU2012268818A1 - Gene involved in immortalization of human cancer cell and use thereof - Google Patents
Gene involved in immortalization of human cancer cell and use thereof Download PDFInfo
- Publication number
- AU2012268818A1 AU2012268818A1 AU2012268818A AU2012268818A AU2012268818A1 AU 2012268818 A1 AU2012268818 A1 AU 2012268818A1 AU 2012268818 A AU2012268818 A AU 2012268818A AU 2012268818 A AU2012268818 A AU 2012268818A AU 2012268818 A1 AU2012268818 A1 AU 2012268818A1
- Authority
- AU
- Australia
- Prior art keywords
- gene
- polypeptide
- determining
- immortalized
- immortalization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 266
- 201000011510 cancer Diseases 0.000 title claims abstract description 252
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 214
- 230000014509 gene expression Effects 0.000 claims abstract description 131
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 98
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 98
- 239000002157 polynucleotide Substances 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims abstract description 80
- 239000000523 sample Substances 0.000 claims abstract description 66
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 168
- 229920001184 polypeptide Polymers 0.000 claims description 167
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 167
- 238000012360 testing method Methods 0.000 claims description 74
- 230000000694 effects Effects 0.000 claims description 53
- 239000000463 material Substances 0.000 claims description 48
- 239000003550 marker Substances 0.000 claims description 47
- 230000000052 comparative effect Effects 0.000 claims description 41
- 239000000126 substance Substances 0.000 claims description 33
- 239000003153 chemical reaction reagent Substances 0.000 claims description 30
- 230000035755 proliferation Effects 0.000 claims description 30
- 230000010261 cell growth Effects 0.000 claims description 24
- 239000003966 growth inhibitor Substances 0.000 claims description 22
- 239000012472 biological sample Substances 0.000 claims description 18
- 238000012216 screening Methods 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 8
- 238000011394 anticancer treatment Methods 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000008569 process Effects 0.000 abstract description 19
- 238000011282 treatment Methods 0.000 abstract description 6
- 230000008685 targeting Effects 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 310
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 80
- 108091081021 Sense strand Proteins 0.000 description 51
- 108020004459 Small interfering RNA Proteins 0.000 description 38
- 108010017842 Telomerase Proteins 0.000 description 36
- 230000001629 suppression Effects 0.000 description 36
- 239000004055 small Interfering RNA Substances 0.000 description 32
- 150000001413 amino acids Chemical group 0.000 description 25
- 108010004145 leukotriene B4 12-hydroxydehydrogenase Proteins 0.000 description 22
- 239000002299 complementary DNA Substances 0.000 description 21
- 101001116751 Homo sapiens Methionine-R-sulfoxide reductase B1 Proteins 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 18
- 238000009396 hybridization Methods 0.000 description 18
- 238000005259 measurement Methods 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 238000001514 detection method Methods 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 17
- 101000594428 Homo sapiens Protein N-lysine methyltransferase METTL21A Proteins 0.000 description 15
- 230000004663 cell proliferation Effects 0.000 description 15
- 230000004913 activation Effects 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000002493 microarray Methods 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 201000005202 lung cancer Diseases 0.000 description 12
- 208000020816 lung neoplasm Diseases 0.000 description 12
- 101150031865 ACVR2B gene Proteins 0.000 description 11
- 101150115468 CHCHD3 gene Proteins 0.000 description 11
- 101000837565 Homo sapiens Ubiquitin-conjugating enzyme E2 S Proteins 0.000 description 11
- 101150074748 LSM3 gene Proteins 0.000 description 11
- 101150029228 PTGES2 gene Proteins 0.000 description 11
- 102100032258 Prostaglandin reductase 1 Human genes 0.000 description 11
- 101150073989 RFC4 gene Proteins 0.000 description 11
- 102100028718 Ubiquitin-conjugating enzyme E2 S Human genes 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 101150024739 dpm2 gene Proteins 0.000 description 11
- 101150039067 maf-1 gene Proteins 0.000 description 11
- 108091035539 telomere Proteins 0.000 description 11
- 102000055501 telomere Human genes 0.000 description 11
- 101150072077 ube2s gene Proteins 0.000 description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 10
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 description 10
- 101150019666 psmA3 gene Proteins 0.000 description 10
- 210000003411 telomere Anatomy 0.000 description 10
- 101150052459 GTSE1 gene Proteins 0.000 description 9
- 101000937269 Homo sapiens Activin receptor type-2B Proteins 0.000 description 9
- 101100338062 Homo sapiens GTSE1 gene Proteins 0.000 description 9
- 102100024874 Methionine-R-sulfoxide reductase B1 Human genes 0.000 description 9
- 102000044159 Ubiquitin Human genes 0.000 description 9
- 108090000848 Ubiquitin Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 201000002528 pancreatic cancer Diseases 0.000 description 9
- 238000000018 DNA microarray Methods 0.000 description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 8
- 102100030484 Prostaglandin E synthase 2 Human genes 0.000 description 8
- 201000004101 esophageal cancer Diseases 0.000 description 8
- 230000009401 metastasis Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000032823 cell division Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102100037488 G2 and S phase-expressed protein 1 Human genes 0.000 description 6
- 101001026457 Homo sapiens G2 and S phase-expressed protein 1 Proteins 0.000 description 6
- 101000582404 Homo sapiens Replication factor C subunit 4 Proteins 0.000 description 6
- 102100030542 Replication factor C subunit 4 Human genes 0.000 description 6
- 238000004040 coloring Methods 0.000 description 6
- 229960002986 dinoprostone Drugs 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 102100027647 Activin receptor type-2B Human genes 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 101001121072 Homo sapiens MICOS complex subunit MIC19 Proteins 0.000 description 5
- 101001136888 Homo sapiens Proteasome subunit alpha type-3 Proteins 0.000 description 5
- 101001055100 Homo sapiens Repressor of RNA polymerase III transcription MAF1 homolog Proteins 0.000 description 5
- 101001017894 Homo sapiens U6 snRNA-associated Sm-like protein LSm3 Proteins 0.000 description 5
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 5
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 5
- 102100026626 MICOS complex subunit MIC19 Human genes 0.000 description 5
- 102100035908 Proteasome subunit alpha type-3 Human genes 0.000 description 5
- 102100026898 Repressor of RNA polymerase III transcription MAF1 homolog Human genes 0.000 description 5
- 102100033313 U6 snRNA-associated Sm-like protein LSm3 Human genes 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 102100020740 Dolichol phosphate-mannose biosynthesis regulatory protein Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000932183 Homo sapiens Dolichol phosphate-mannose biosynthesis regulatory protein Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 102100035607 Protein N-lysine methyltransferase METTL21A Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007976 Tris-NaCl-Tween buffer Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- SJVWVCVZWMJXOK-NOJHDUNKSA-N 12-dehydro-leukotriene B4 Chemical compound CCCCC\C=C/CC(=O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O SJVWVCVZWMJXOK-NOJHDUNKSA-N 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 3
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 230000009702 cancer cell proliferation Effects 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 238000003633 gene expression assay Methods 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 230000001459 mortal effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000012857 radioactive material Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LLQPHQFNMLZJMP-UHFFFAOYSA-N Fentrazamide Chemical compound N1=NN(C=2C(=CC=CC=2)Cl)C(=O)N1C(=O)N(CC)C1CCCCC1 LLQPHQFNMLZJMP-UHFFFAOYSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 101001013208 Homo sapiens Mediator of RNA polymerase II transcription subunit 15 Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100029663 Mediator of RNA polymerase II transcription subunit 15 Human genes 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000013668 Prostaglandin E synthase 2 Human genes 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 102000018478 Ubiquitin-Activating Enzymes Human genes 0.000 description 2
- 108010091546 Ubiquitin-Activating Enzymes Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 238000010293 colony formation assay Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 101150072531 10 gene Proteins 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- 101150098072 20 gene Proteins 0.000 description 1
- 101150110188 30 gene Proteins 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102400000011 Cytochrome b-c1 complex subunit 9 Human genes 0.000 description 1
- 101800000778 Cytochrome b-c1 complex subunit 9 Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 108010087568 Mannosyltransferases Proteins 0.000 description 1
- 102000006722 Mannosyltransferases Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- GYBNOAFGEKAZTA-QOLULZROSA-N [(6z,10e,14e)-3,7,11,15,19-pentamethylicosa-6,10,14,18-tetraenyl] dihydrogen phosphate Chemical compound OP(=O)(O)OCCC(C)CC\C=C(\C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C GYBNOAFGEKAZTA-QOLULZROSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 108010057453 activin receptor type II-B Proteins 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003431 anti-prostaglandin Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001100 crypt cell Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000000659 freezing mixture Substances 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005205 gut mucosa Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- -1 polynucleotides) Chemical class 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011470 radical surgery Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention provides a gene related to cancer cell immortalization (an immortalization determining gene) and 5 a process that is useful for selective cancer treatment targeting a cancer cell having the gene. The present invention determines an immortalized cancer cell using a polynucleotide having a base sequence of at least 15 bases that specifically hybridizes with a continuous base sequence 10 of at least 15 bases within any one of abase sequences represented by SEQ ID Nos. 1 to 13. In the foregoing process, the polynucleotide is used as a primer or probe for detecting an immortalization determining gene that exhibits high expression specifically in an immortalized cancer cell. 3956219_1 (GHMatters) P79759.AU.1
Description
-2 GENE INVOLVED IN IMMORTALIZATION OF HUMAN CANCER CELL AND USE THEREOF TECHNICAL FIELD 5 [0001] The entire disclosure in the complete specification of our Australian Patent Application No. 2007255677 is by this cross-reference incorporated into the present specification. [0001a] 10 The present invention relates to a gene (immortalization-determining gene) involved in the immortalization of human cancer cells, and a method useful for a selective cancer therapy targeting an immortalized cancer cell having the gene. More specifically, the present 15 invention relates to a method for discriminating an immortalized cancer cell using an immortalization-determining gene as an index, and a reagent for the discrimination. The present invention further relates to a method for screening an active ingredient of a selective anticancer drug (immortalized 20 cancer cell growth inhibitor) targeting immortalized cancer cells, and the anticancer drug (immortalized cancer cell growth inhibitor). BACKGROUND ART 25 [0002] Patients are given a poor prognosis for human solid cancer unless radical surgery is performed. This mainly derives from the insufficient effect of the present chemotherapy. Since existing chemotherapy drugs basically 30 influence the nucleic acid biosynthesis, DNA, microtubule, etc., as they inhibit the synthesis process from nucleic acid into protein, they inevitably damage, in addition to cancer cells, healthy cells that are in the process of cell growth. 3956219_1 (GHMatters) P79759.AU.1 -3 Recent research has identified a number of molecules that are specifically expressed in cancer cells, and inhibitors that target these specific molecules can have a minimal adverse reaction to healthy cells. This advantage allows for a 5 greater dosage of the drug. However, in spite of its active development, such a molecule-targeted drug has the following major defect. The molecule-targeted drug does not necessarily promise a certain effect on a majority of cancer cases; the effect can greatly vary for each case. Moreover, it is 10 usually difficult to precisely estimate the effect before the administration. Such a great variation in a molecule-targeted therapeutic drug in each case can derive from the fact that the drug is directed to the molecules of genes involved in carcinogenesis or metastasis. Carcinogenesis varies among 15 different types of cancer and even within the same cancer; therefore, it is assumed that the effect of the targeted molecules on the cancer growth differs in each case. Conversely, the development of a molecule-targeted therapeutic drug that can exhibit a universal effect on many cancers 20 should become possible by identifying a molecule that has a universal and primary effect on various types of cancers. [00031 In all vertebrates, including humans, each chromosome end contains a simple iteration sequence: "TTAGGG" (about 10kb 25 in humans and several times greater in mice). This terminal sequence cannot be thoroughly reproduced at every DNA duplication upon cell division, and is gradually shortened (on the basis of about 200 bases in humans). This terminal portion is called a "telomere". When a telomere is shortened 30 to a certain length (about 5kb in human noncancerous cells) by repeated cell divisions, the cell division eventually ceases. Cell division again becomes possible by cell canceration, but then, when the curtailment finally comes to the ultimate level 3956219_1 (GHMatters) P79759.AU.1 -4 (about 2kb), the cell dies. As disclosed in Non-Patent Document 1, reverse transcriptase "telomerase" serves to extend the shortened telomere to stabilize the telomere length, thereby prolonging the cell division limit. Because the 5 telomerase is not expressed in a healthy cell, the cell division in a healthy cell is limited to several tens of times. However, the telomerase is highly expressed in both a productive cell and an immortalized cancer cell. All cancer cells used to be regarded as immortal; however, reports have 10 revealed that some clinically evident cancers did not exhibit telomerase activities (see Non-Patent Documents 2, 3, etc.). Other reports have also revealed that the compulsory expression of telomerase enzyme component TERT in a noncancerous cell did not produce a cancer cell (see Non 15 Patent Document 4). Accordingly, at present, canceration and immortalization are recognized as different phenomena. [Non-Patent Document 1] Harley CB, Mutation Res, 256: 271-82, 1991 [Non-Patent Document 2] Kim NW et al., Science 266: 2011-5, 20 1994 [Non-Patent Document 3] Hiyama K et al., J Natl Cancer Inst 87: 895-902, 1995 [Non-Patent Document 4] Morales CP et al., Nat Genet 21: 115 8, 1999 25 [Non-Patent Document 5] Shay JW, Bacchetti S, Eur J Cancer 33: 787-91, 1997 [Non-Patent Document 6] Hiyama K et al., J Immunol 155: 3711 5, 1995 [Non-Patent Document 7] Hiyama E et al., Int J Oncol 9: 453-8, 30 1996 [Non-Patent Document 8] Forsyth NR et al., Aging Cell 2: 235 43, 2003 [Non-Patent Document 9] Bodnar AG et al., Exp Cell Res 228: 3956219_1 (GHMatters) P79759.AU.1 -5 58-64, 1996 [Non-Patent Document 10] Hiyama K et al., Int J Oncol 27: 87 95, 2005 [0003a] 5 It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country. 10 DISCLOSURE OF INVENTION Technical Problem [0004] The present invention relates to a method for 15 discriminating an immortalized cancer cell, and a reagent used for the discrimination. The present invention further relates to a method for screening an active ingredient for an immortalized cancer cell growth inhibitor that is useful as a selective anticancer drug due to its effect of specifically 20 suppressing immortalized cancer cell growth; and the immortalized cancer cell growth inhibitor. Technical Solution [00051 In order to develop a molecule-targeted therapeutic drug 25 that is effective for cancer treatment, especially a drug that is expected to have a universal effect on many types of cancers, the inventors of the present invention focus their attention on another character of cancer, "immortalization", that is different from "canceration (malignant alteration)". 30 Specifically, even if cancer cells are found, they will not spread or metastasize to kill the host if their limitless growth can be stopped. The suppression of the limitless growth also increases the possibility of the natural death of 3956219_1 (GHMatters) P79759.AU.1 -6 cancer cells given that the number of residual cancer cells is reduced by chemotherapy or nonradical surgery to some extent, because it is expected that the cancer cell division term would run out before the next cell growth begins. It has been 5 reported that telomerase expression was seen in 80% or more of several thousands of clinical specimens (see Non-Patent Document 5); telomerase expression was confirmed in various types of cancers examined to date; and telomerase expression was seen in most of the cell strains that derive from human 10 cancers (see Non-Patent Document 2) . Based on these reports and the known fact that cancer cells containing telomerase expression will never naturally turn negative again, the immortalization phenomenon seems to exist universally and commonly in many cancer cells, in contrast to the wide variety 15 of carcinogenesis. Accordingly, by targeting the molecule that regulates immortalization, it becomes possible to suppress infinite cancer growth with a universal effect on many types of cancers. Based on this principle, an anti cancer strategy that directly focuses on telomerase has been 20 tested. [00061 However, the inventors of the present invention had already found that a precursor cell, lymphocyte, etc., of a regenerating organ exhibits telomerase activation even in a 25 normal healthy cell (see Non-Patent Documents 6 and 7). It is also known that cell immortalization is not always induced by compulsive expression of TERT (telomerase enzyme component) in noncancerous cells (see Non-Patent Document 8); and that the healthy precursor cell or lymphocyte that expresses telomerase 30 is not immortalized but has a prolonged life (see Non-Patent Documents 6 and 9). Accordingly, such exhibition of telomerase activation in healthy cells is obviously merely telomerase expression rather than cell immortalization. More 3956219_1 (GHMatters) P79759.AU.1 -7 specifically, though human cell immortalization substantially requires the activation of a telomerase enzyme that serves to extend the telomere in the chromosome terminus, the immortalization is not induced only by the telomerase 5 activation, but also by the presence of specific molecules for immortalization. The molecules seem to function particularly in cancer cells. In fact, the inventors of the present invention confirmed that a gene that specifically undergoes expression and change in a clone, which has been immortalized 10 by compulsive telomerase expression through the introduction of TERT into healthy cells, completely differs from the reported expression and change seen in cancer cells (see Non Patent Document 10). This is another fact indicating that the gene involved in the immortalization of healthy cells differs 15 from the gene involved in the immortalization of cancer cells. If the drug is directed to telomerase, it suppresses the division ability of the lymphocyte, blood precursor cell, gut mucosa crypt cell, etc., and thereby tends to damage immunity, hematogenous ability, and gastrointestinal function, which is 20 known to be a fatal harm in cancer treatment. However, if the drug is directed to a immortalization-determining factor that works only in cancer cells, it becomes possible to block the specific infinite proliferation of cancer cells without damaging the healthy trunk/precursor cells having telomerase 25 activities. [0007] Based on this theory, the inventors of the present invention conducted an intensive study to discover genes that are universally involved in the immortalization of human 30 cancer cells. As a result of the research, the inventors of the present invention eventually realized that those genes are not involved in the lifetime extension of cells resulting from telomerase activation in healthy cells, but is specifically 3956219_1 (GHMatters) P79759.AU.1 -8 involved in the constant proliferation of cancer cells. The inventors then identified thirteen immortalization-determining genes (Table 1) in the following manner. First, the genes that are universally expressed and strengthened in various 5 types of cancers were extracted by microarray assay. Among the obtained genes, thirteen kinds of genes were selected on the basis of their expression in a clinical cancer organ consisting of immortalized cancer cells being stronger than the expression of a cancerous tissue comprised of non 10 immortalized cancer cells and that undergoing no expression or augmentation in healthy cells expressed by the introduction of telomerase. Then, the inventors confirmed that suppressing the expression of the thirteen genes using siRNA suppresses the proliferation of immortalized cancer cells. 15 [00081 The inventors of the present invention further conducted more detailed research based on the foregoing theory, and eventually completed the present invention. Specifically, the present invention includes the following forms. 20 Item 1. A marker gene for determining cancer cell immortalization, the marker gene comprising a polynucleotide having a base sequence of at least 15 bases that specifically hybridizes with a continuous base sequence of at least 15 bases within any one of base sequences represented by SEQ ID 25 Nos. 1 to 13. [00091 Item 2. The marker gene according to Item 1, wherein the marker gene is a probe or primer. [0010] 30 Item 3. A method for determining an immortalized cancer cell, comprising the steps of: (1) bonding the marker gene according to claim 1 or 2 with RNA prepared from a biological sample that is extracted 3956219_1 (GHMatters) P79759.AU.1 -9 from a test subject and that may contain a cancer cell, or a derivative of the RNA; (2) measuring an amount of the RNA or the derivative bonded with the marker gene, using the marker gene as an 5 index; and (3) comparing the amount of RNA or the derivative thereof found in Step (2) (generically referred to as "an RNA amount", hereinafter) with an amount (generically referred to as "a comparative RNA amount", hereinafter) of a corresponding 10 RNA or a derivative thereof in a non-immortalized healthy or cancer cell. [0011] Item 4. The method for determining an immortalized cancer cell according to Item 3, further comprising the step of: 15 (4) determining that the cancer cell of the test subject is immortalized when the RNA amount found in Step (2) is higher than the comparative RNA amount, and determining that the cancer cell of the test subject is not immortalized when the RNA amount found in Step (2) is not higher than the 20 comparative RNA amount. [0012] Item 5. An antibody for recognizing a polypeptide having any one of amino acid sequences represented by SEQ ID Nos. 14 to 26. The antibody is suitable for use in determining an 25 immortalized cancer cell. [0013] Item 6. A method for determining an immortalized cancer cell, comprising the step of: (1') bonding a protein-containing fraction containing a 30 polypeptide prepared from a biological sample that is extracted from a test subject and that may contain a cancer cell with the antibody according to Item 5; (2') measuring the amount of the polypeptide that is 3956219_1 (GHMatters) P79759.AU.1 -10 bonded with the antibody, using the antibody as an index; and (3') comparing the amount (generically referred to as "a polypeptide amount", hereinafter) of the polypeptide found in Step (2') with the amount (generically referred to as "a 5 comparative polypeptide amount", hereinafter) of a corresponding polypeptide in a non-immortalized healthy or cancer cell. [0014] Item 7. The method for determining an immortalized cancer 10 cell according to Item 6, further comprising the step of: (4') determining that the cancer cell of the test subject is immortalized when the polypeptide amount found in Step (2') is higher than the comparative polypeptide amount, and determining that the cancer cell of the test subject is 15 not immortalized when the polypeptide amount found in Step (2') is not higher than the comparative polypeptide amount. [0015] Item 8. An immortalized cancer cell determining reagent kit including at least one member selected from the group 20 consisting of the marker gene according to Item 1 and the antibody according to Item 5. [0016] Item 9. A method for screening a substance for suppressing proliferation of immortalized cancer cells, comprising the 25 steps of: (A) bringing a test material into contact with a cell that can express one of the immortalization-determining genes represented by SEQ ID Nos. 1 to 13; (B) measuring an expression amount of the 30 immortalization-determining gene in the cell brought into contact with the test material; (C) comparing the expression amount of the immortalization-determining gene found in Step (B) with an 3956219_1 (GHMatters) P79759.AU.1 -11 expression amount (generically referred to as "a comparative expression amount", hereinafter) of an immortalization determining gene in a cell not in contact with the test material; and 5 (D) selecting the test material as a candidate substance for suppressing proliferation of immortalized cancer cells when the expression amount found in Step (B) is lower than the comparative expression amount. [0017] 10 Item 10. A method for screening a substance for suppressing proliferation of immortalized cancer cells, comprising the steps of: (A') bringing a test material into contact with a polypeptide having one of the amino acid sequences represented 15 by SEQ ID Nos. 14 to 26; (B') measuring activity of the polypeptide having one of the amino acid sequences represented by SEQ ID Nos. 14 to 26 brought into contact with the test material; (C') determining the degree of the activity of the 20 polypeptide found in Step (B') by comparing the activity of the polypeptide found in Step (B') with activity (generically referred to as "a comparative activity", hereinafter) of a polypeptide not in contact with the test material; and (D') selecting the test material as a candidate 25 substance for suppressing proliferation of immortalized cancer cells when the activity of the polypeptide found in Step (B') is lower than the comparative activity. [0018] Item 11. An immortalized cancer cell growth inhibitor 30 containing, as an active ingredient, a polynucleotide having a base sequence of at least 15 bases that specifically hybridizes with a continuous base sequence of at least 15 bases within any one of base sequences represented by SEQ ID 3956219_1 (GHMatters) P79759.AU.1 -12 Nos. 1 to 13. [0019] Item 12. The immortalized cancer cell growth inhibitor according to Item 11, wherein the polynucleotide has one of 5 base sequences represented by SEQ ID No. 27 to 39. [0020] Item 13. A method of anticancer treatment comprising the step of administering the immortalized cancer cell growth inhibitor according to Item 11 or 12 to cancer cells of a 10 patient. [0021] Item 14. Use of a polynucleotide having a base sequence of at least 15 bases that specifically hybridizes with a continuous base sequence of at least 15 bases within one of 15 base sequences represented by SEQ ID Nos. 1 to 13, for producing an immortalized cancer cell growth inhibitor. [0022] Item 15. The use according to Item 14, wherein the polynucleotide has one of base sequences represented by SEQ ID 20 Nos. 27 to 39. EFFECT OF THE INVENTION [0023] The present invention discovered genes that universally 25 determine the immortalization of many different cancer cells. The genes specifically exhibit greater expression in immortalized cancer cells in a plurality of cancers. The present invention provides a method for discriminating immortalized cancer cells, and a reagent that is used for the 30 discrimination method, which allows for measuring the expression level of the immortalization-determining genes. Referring to the measured level, it becomes possible to distinguish the immortalized cancer cells from finite cells. 3956219_1 (GHMatters) P79759.AU.1 -13 This differentiation was never possible in conventional general pathological diagnoses. The differentiation thus has great potential as a clinical application that is useful for early diagnosis, new treatment options, prognostification, and 5 the like of various cancers. [0024] Further, with a screening process targeting an immortalization-determining gene of the present invention, an active ingredient of an anticancer drug that specifically 10 suppresses the proliferation of immortalized cancer cells is obtained. [0024a] In the claims which follow and in the description of the invention, except where the context requires otherwise due to 15 express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention. 20 BEST MODE FOR CARRYING OUT THE INVENTION [0025] (I) Immortalization-determining gene In the present invention, the term "non-immortalized cancer 25 cells" refers to, among general cancer cells, a finite cell having (1) negative telomerase-activation, (2) a reduced telomere length, and (3) undetectable expression of a telomerase protein. Further, in the present invention, the term "immortalized cancer cell" refers to a cell that lacks at 30 least one of the aforementioned conditions; more specifically, a cell having telomerase activation, a cell having an extended telomere length, and/or a cell detectable expression of a telomerase protein. Such an "immortalized cancer cell" is 3956219_1 (GHMatters) P79759.AU.1 -14 capable of limitless cell proliferation. [0026] In the present invention, the term "immortalization determining gene" refers to a gene that determines the 5 immortalization of cancer cells. [0027] The present invention does not particularly limit the type of cancer cell as a target, and includes cells that derive from, for example, lung cancer, breast cancer, 10 esophagus cancer, head and neck cancer, gastric cancer, colon cancer, rectal cancer, liver cancer, gallbladder and bile duct cancer, pancreatic cancer, bladder cancer, prostatic cancer, or uterine cervix carcinoma. [0028] 15 The immortalization-determining genes are, namely, (1) UBE2S gene, (2) RFC4 gene, (3) PTGES2 gene, (4) MAF1 gene, (5) ACVR2B gene, (6) FAM119A gene, (7) LTB4DH gene, (8) DPM2 gene, (9) SEPX1 gene, (10) PSMA3 gene, (11) CHCHD3 gene, (12) LSM3 gene, and (13) GTSE1 gene. Table 1 shows the GenBank 20 accession number, formal gene name, and gene symbol of the foregoing genes, and the SEQ ID No.s indicating the base sequences of the genes. In Table 1, the gene name, gene symbol, etc., are based on NCBI data disclosed on the Internet (http://www.ncbi.nlm.nih.gov/). 25 3956219_1 (GHMatters) P79759.AU.1 -15 [0029] Table 1 GenBank SEQ ID Gene Accession Gene Name No. Symbol No. 1 NM 014501 ubiquitin-conjugating enzyme E2S LBES 2 2 NM 002916 replication factor C (activator 1) 4, 37kDa RFC4 3 NM_025072 prostaglandin E synthase 2 PTCES2 4 NM 032272 MAFI homolog (S. cerevisiae) WAF 5 NM 001106 activin A receptor, type TTB ACVR2B 6 NM_145280 family with sequence similarity 119, member A FAWI19A NM_012212 7 (D49387, leukotriene B4 12-hydroxydehydrogenase L TB4DH BQ214856) dolichyl-phosphate mannosyltransferase polypeptide 8 NM 003863 DPW2 2, regulatory subunit 9 NM_016332 selenoprotein X, 1 SEPX1 proteasome (prosome, macropain) subunit, alpha type, 10 NM 002788 PSWA3 3 coiled-coil-helix-coiled-coil-helix domain 11 NM 017812 CHCHD3 containing 3 LSM3 homolog, U6 small nuclear RNA associated (S. 12 NM 014463 LSW3 cerevisiae) 13 NM_016426 G-2 and S-phase expressed 1 GTSE1 5 [0030] As shown in Example 1, the above-listed immortalization determining genes are all highly expressed in immortalized cancer cells derived from a plurality of cancers, including 10 lung cancer, esophagus cancer, and breast cancer. As shown in Example 2, when the expression of these thirteen genes was suppressed by siRNA in the immortalized cancer cells, in every case, the proliferation of immortalized cancer cells was 3956219_1 (GHMatters) P79759.AU.1 -16 suppressed. This shows that the thirteen immortalization determining genes determine the immortalization of cancer cells (immortalization-determining gene). [0031] 5 (II) Reagent for judging the immortalization of cancer cells (marker gene) As described above, the immortalization-determining genes ((1) to (13)) having base sequences represented by SEQ ID No.s 1 to 13 are all highly expressed specifically in 10 immortalized cancer cells. Therefore, using the thirteen genes as marker genes, the immortality/mortality of cancer cells can be judged. [0032] The present invention provides an immortalization 15 determining marker gene (abbreviated as "marker gene" in the present invention) as a tool (reagent) that is suitably used to judge the immortalization of cancer cells. The marker gene is designed as a polynucleotide of at least 15 bases that specifically hybridizes with a continuous base sequence of at 20 least 15 bases among one of the base sequences of the immortalization-determining genes represented by the SEQ ID No.s 1 to 13. The marker gene of the present invention may have an arbitrary form according to the object, and may be any of single-strand DNA, single-strand RNA, double-strand DNA, 25 double-strand RNA, and DNA:RNA hybrid. [0033] The marker gene contains a probe or primer useful for detecting the occurrence of expression of an immortalization determining gene and/or the level (expression level) in cancer 30 cells to allow for the discrimination of immortalized cancer cells. Further, the probe or primer is also useful as a tool (detection reagent) for detecting the expression variation of an immortalization-determining gene in the screening of a 3956219_1 (GHMatters) P79759.AU.1 -17 material that suppresses the proliferation of the immortalized cancer cells. [0034] (II-1) Probe 5 The immortalization of cancer cells is discriminated by detecting at least one of the above-mentioned immortalization determining genes: (1) UBE2S gene, (2) RFC4 gene, (3) PTGES2 gene, and (4) MAF1 gene, (5) ACVR2B gene, (6) FAM119A gene, (7) LTB4DH gene, (8) DPM2 gene, (9) SEPX1 gene, (10) PSMA3 10 gene, (11) CHCHD3 gene, (12) LSM3 gene, and (13) GTSE1 gene, which are highly expressed specifically in the immortalized cancer cells. [00351 The detection of the immortalization-determining genes 15 uses, as probes, polynucleotides, each of which specifically hybridizes with the base sequence of one of the aforementioned immortalization-determining genes. In the present invention, an oligonucleotide having plural base sequences is included in the range of "polynucleotide". 20 [00361 Each polynucleotide is designed to specifically hybridize with a continuous base sequence of one of the immortalization-determining genes. More specifically, for each of the aforementioned immortalization-determining genes, 25 a corresponding polynucleotide specifically hybridizes with a continuous base of at least 15 bases, preferably 20 bases, and more preferably 30 bases to the total base length of the immortalization-determining gene. Accordingly, each polynucleotide has a base length corresponding to the defined 30 base length. [0037] Throughout the present specification and claims, "specific hybridization" refers to a hybridization that forms 3956219_1 (GHMatters) P79759.AU.1 -18 only a specific hybrid and does not form a nonspecific hybrid under a stringent hybridization condition. The stringent hybridization condition is determined in the usual manner, for example, based on the melting temperature (Tm) of the nucleic 5 acid at which the hybrid is formed. A typical cleaning condition to ensure the hybridization condition is approximately "1xSSC, 0.1%SDS, 370C", more strictly "0.5xSSC, 0.1%SDS, 420C", and yet more strictly "0.1xSSC, 0.1%SDS, 650C". [00381 10 The polynucleotide (probe) preferably has a base sequence that is complementary to a continuous base sequence of at least 15 bases of the immortalization-determining gene; however, the probe is not always required to be fully complementary to said continuous base sequence as long as the 15 specific hybridization is possible. The polynucleotide has an identity of at least 70%, preferably not less than 80%, more preferably not less than 90%, yet more preferably not less than 95%, and still more preferably not less than 98%, with respect to either the polynucleotide having a continuous base 20 of at least 15 bases within a base sequence of the immortalization-determining gene or the complementary polynucleotide thereof. The identity of each base sequence can be calculated by way of an identity search, alignment program, BLAST, FASTA, ClustalW, or the like. 25 [00391 Examples of probes suitable for the present invention include oligonucleotides and polynucleotides having a continuous base sequence of 15 bases, preferably 20 bases, and more preferably 30 bases to the total base length of the 30 immortalization-determining gene that hybridizes with at least one polynucleotide (however, when the polynucleotide is RNA, the base "t" in the sequence is replaced with "u") selected from the group consisting of the following (1) to (13). 3956219_1 (GHMatters) P79759.AU.1 -19 [0040] (1) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.1) of the UBE2S gene. 5 (2) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.2) of the RFC4 gene. (3) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.3) of the 10 PTGES2 gene. (4) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.4) of the MAF1 gene. (5) A polynucleotide with a continuous base sequence having at 15 least 15 bases from the base sequence (SEQ ID No.5) of the ACVR2B gene. (6) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.6) of the FAM119A gene. 20 (7) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.7) of the LTB4DH gene. (8) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.8) of the 25 DPM2 gene. (9) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.9) of the SEPX1 gene. (10) A polynucleotide with a continuous base sequence having 30 at least 15 bases from the base sequence (SEQ ID No.10) of the PSMA3 gene. (11) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.11) of the 3956219_1 (GHMatters) P79759.AU.1 -20 CHCHD3 gene. (12) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.12) of the LSM3 gene. 5 (13) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.13) of the GTSE1 gene. [0041] These polynucleotides (probes) can be produced by a 10 known method, for example, using a commercially available nucleotide synthesizer, based on the target base sequence of the immortalization-determining gene. The polynucleotides (probes) can also be produced by the PCR method using the target base sequence of the immortalization-determining gene 15 as a template. [0042] More preferably, to simplify detection of the immortalization-determining genes, each probe may be labeled with a radioactive material, a fluorescent material, a 20 chemical luminescent substance or an enzyme (described later in greater detail). [0043] Further, each probe may be immobilized in an arbitrary solid phase before use. 25 Accordingly, the probes suitable for the present invention include a probe in which an aforementioned polynucleotide is immobilized in a solid phase (for example, an immobilized probe, including a gene chip, a cDNA microarray, an oligo DNA array, or a membrane filter.). This probe is suitable for a 30 DNA chip for use in immortalization-determining gene detection, or more specifically, for use in immortalized cancer cell detection. 3956219_1 (GHMatters) P79759.AU.1 -21 [0044] The solid phase of the immobilized probe (polynucleotide) is not particularly limited as long as it immobilizes the polynucleotide. Examples of solid phases 5 include a glass plate, a nylon membrane, micro beads, a silicon chip, a capillary, and other substrates. The polynucleotide can be immobilized in the solid phase by disposing a synthetic polynucleotide in a solid phase, or by synthesizing a target polynucleotide in a solid phase. The 10 immobilization is a well known technology in the present field, and any suitable method can be used according to the type of immobilized probe. For example, a commercially available spotter (manufactured by Cosmobio Co., Ltd., etc.) is often used to form a DNA microarray. (For example, polynucleotide in 15 situ synthesis using photolithographic technology (AFFYMETRIX CO.), or inkjet technology (ROSETTA INPHARMATICS CO.) [0045] (11-2) Primer The present invention provides a polynucleotide as a 20 primer that serves as a marker gene to specifically amplify a base sequence region of each immortalization-determining gene. [0046] The polynucleotide is typically a polynucleotide that has a continuous base sequence of at least 15 bases, 25 preferably 15 to 100 bases, more preferably 15 to 50 bases, yet more preferably 15 to 35 bases, and that specifically hybridizes with a part of at least one polynucleotide (however, when the polynucleotide is RNA, the base "t" in the sequence is replaced with "u") selected from the group consisting of 30 the following (1) to (13), so as to amplify part or all of the polynucleotide. [0047] (1) A polynucleotide with a continuous base sequence having at 3956219_1 (GHMatters) P79759.AU.1 -22 least 15 bases from the base sequence (SEQ ID No.1) of the UBE2S gene. (2) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.2) of the 5 RFC4 gene. (3) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.3) of the PTGES2 gene. (4) A polynucleotide with a continuous base sequence having at 10 least 15 bases from the base sequence (SEQ ID No.4) of the MAF1 gene. (5) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.5) of the ACVR2B gene. 15 (6) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.6) of the FAM119A gene. (7) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.7) of the 20 LTB4DH gene. (8) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.8) of the DPM2 gene. (9) A polynucleotide with a continuous base sequence having at 25 least 15 bases from the base sequence (SEQ ID No.9) of the SEPX1 gene. (10) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.10) of the PSMA3 gene. 30 (11) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.11) of the CHCHD3 gene. (12) A polynucleotide with a continuous base sequence having 3956219_1 (GHMatters) P79759.AU.1 -23 at least 15 bases from the base sequence (SEQ ID No.12) of the LSM3 gene. (13) A polynucleotide with a continuous base sequence having at least 15 bases from the base sequence (SEQ ID No.13) of the 5 GTSE1 gene. [0048] As with the probe, each of the defined polynucleotides (primers) preferably has a base sequence complementary to the continuous base sequence of at least 15 bases in one of the 10 immortalization-determining genes; however, as long as a specific hybridization is possible, it is not required to be totally complementary. The polynucleotide preferably has an identity of at least 70%, preferably not less than 80%, more preferably not less than 90%, yet more preferably not less 15 than 95%, and still more preferably not less than 98%, with respect to either the polynucleotide having a continuous base of at least 15 bases within a sequence of the immortalization determining gene or the complementary polynucleotide thereof. [0049] 20 As with the probes, these polynucleotides (primers) can be produced by a known method, for example, using a commercially available nucleotide synthesizer, based on the target base sequence of the immortalization-determining gene. [00501 25 (11-3) Marker The marker gene (probe or primer) according to the present invention may be a product obtained by adding a marker suitable for detecting an immortalization-determining gene, such as a fluorescent coloring material, an enzyme, a protein, 30 a radioisotope, a chemical luminescent substance, or a biotin, to the aforementioned polynucleotide. [0051] For example, a suitable example of the marker of the 3956219_1 (GHMatters) P79759.AU.1 -24 present invention made of a fluorescent coloring material, a radioisotope, or a chemical luminescent substance is a general marker capable of labeling a nucleotide to detect or determine the quantity of nucleic acids. Examples of fluorescent 5 coloring materials include, but are not limited to, HEX (4, 7, 2', 4', 5', 7'-hexachloro-6-carboxylfluorescein, green fluorescent coloring material), fluoresceine, NED (product name; Applied Biosystems Inc., yellow fluorescent coloring material), 6-FAM (product name; Applied Biosystems Inc, 10 yellowish green fluorescent coloring material), and rhodamine or its derivative (e.g., tetra methyl rhodamine (TMR)). Fluorescent color labeling on a nucleotide is performed by a suitable method among the known labeling methods (see Nature Biotechnology, 14, 303-308 (1996)). A commercially available 15 fluorescent label kit (for example, oligonucleotide ECL 3' oligo labeling system produced by Amersham Pharmacia Biotech) can also be used. [0052] The above-described marker gene (an unlabeled or labeled 20 probe or primer) may be used as an immortalization-determining gene detection reagent, in other words, an immortalized cancer cell detection reagent. [00531 (11-4) Immortalized cancer cell detecting reagent kit 25 The present invention further provides an immortalized cancer cell detecting reagent (marker gene (an unlabeled or labeled probe or primer)) kit. The kit includes at least one of the above mentioned unlabeled or labeled polynucleotides used as probes or primers (the polynucleotide may be 30 immobilized in a solid phase). In addition to the marker gene (probe or primer), the reagent kit of the present invention may include other reagents or tools as required during the actual performance (described later) of the method of the 3956219_1 (GHMatters) P79759.AU.1 -25 present invention, such as a hybridization reagent, a probe labeling material, a label detecting agent, a buffer solution etc. [0054] 5 (III) Determination method for immortalized cancer cells (III-1) The marker gene (probe or primer) of the present invention enables measurement of the expression amount of the immortalization-determining gene (marker gene) in the cancer cells obtained from a test subject; further, the measured 10 expression amount enables judgment as to whether the cancer cells are "immortalized cancer cells" or "non-immortalized cancer cells". Existing pathological diagnoses are incapable of determining immortalized cancer cells; however, the immortalized cancer cell determination method of the present 15 invention is capable of detecting the early-stage of incipient immortalized cancer cells even before they develop, thereby allowing for rapid provision of an appropriate cancer treatment for each individual. [00551 20 In this case, the primer and the probe of the present invention are used as a primer for specifically recognizing and amplifying an RNA resulting from the expression of an immortalization-determining gene or a polynucleotide produced from the RNA (e.g., cDNA), and as a probe for specifically 25 detecting an RNA, or a polynucleotide (e.g., cDNA, DNA amplified from RNA or cDNA) that derives from an RNA, respectively. [00561 More specifically, the marker gene (primer or probe) of 30 the present invention may be used as a primer and/or a probe for specifically detecting an immortalization-determining gene, using a known method for specifically detecting a specific gene, such as the northern blotting method, an RT-PCR method, 3956219_1 (GHMatters) P79759.AU.1 -26 an in situ hybridization method, or the like. Further, detection and/or quantity determination of the expression amount of the immortalization-determining gene in the cancer cell may be performed using a DNA chip. In this case, the 5 probe of the present invention can be used as a probe for the DNA chip. [0057] For example, the measurement of the expression amount of the immortalization-determining gene by way of the northern 10 blotting method may be performed with the probe of the present invention, or more preferably, by the probe labeled with a radioisotope, a fluorescent material, or a chemical luminescent substance. More specifically, RNA extracted from a cancer cell of a test subject is transferred to a nylon 15 membrane or the like, and the labeled probe is hybridized with the RNA. Then, the amount of the resulting double-strand of the probe and the RNA is measured based on a signal given by the marker of the probe. The detection of the signal may be carried out by an appropriate known tool according to the 20 marker of the probe, such as a radiation detector, or a fluorescence detector. Detection may also be performed with a commercially available northern blotting reagent kit in accordance with the protocol of the kit. [00581 25 Measurement of the immortalization-determining gene expression amount using the RT-PCR method may also be performed using a primer of the present invention, preferably, a primer labeled with a radioisotope, a fluorescent material, a chemical luminescent substance, or the like. More 30 specifically, a pair of marked primers is hybridized with a template cDNA prepared from RNA deriving from a cancer cell of a test subject, and PCR is performed in the general manner. Then, the amount of the resulting amplified double-strand DNA 3956219_1 (GHMatters) P79759.AU.1 -27 is measured based on the signal given by the marker of the primer. The detection of the signal may be carried out by an appropriate known tool, such as a radiation detector, or a fluorescence detector. The detection may also be performed 5 with a commercially available RT-PCR reagent kit in accordance with the protocol of the kit. [00591 Measurement of the expression amount of an immortalization-determining gene using a DNA chip assay may 10 also be carried out using a probe of the present invention, preferably, a probe labeled with a radioisotope, a fluorescent material, etc. More specifically, a DNA chip, in which a probe labeled with a radioisotope, a fluorescent material, a chemical luminescent substance, or the like, is fixed to an 15 appropriate carrier. Then, the DNA chip is hybridized with a marked DNA or RNA that is prepared from RNA deriving from a cancer cell of a test subject. Then, the amount of the resulting double-strand of the probe and marked DNA or RNA is measured based on the signal given by the marker of the probe. 20 Detection of the signal may be carried out by an appropriate known tool such as a radiation detector or a fluorescence detector. This method may be performed with a commercially available DNA chip in which DNA corresponding to a probe of the present invention is fixed. 25 [00601 Measurement of the expression amount of immortalization determining genes includes the following two steps (1) and (2). (1) a step of bonding a probe or primer of the present invention to RNA prepared from a biological sample that may 30 contain a cancer cell obtained from a test subject, or a derivative of the RNA; and (2) a step of measuring the amount of the RNA or derivative thereof bonded with the probe or primer, using the probe or 3956219_1 (GHMatters) P79759.AU.1 -28 primer as an index. [0061] In Step (1), the biological sample can be any sample extracted from a test subject, as long as it has the potential 5 to contain a cancer cell. Examples of the biological sample include body fluid (blood, urine, etc.), tissues, or the extracts thereof, and cultures of the obtained tissues. Extraction of the biological sample from the test object is performed by an appropriate method according to the type of 10 biological sample or type of cancer. Preparation of the RNA from the biological sample is performed by a known method. [0062] Throughout the specification and claims, the term "an RNA derivative" refers to a sample produced by RNA extracted 15 from a biological sample. Examples of an RNA derivative include a complementary polynucleotide (cDNA) prepared by RNA transcription, and DNA amplified from the RNA or cDNA using PCR. The cDNA may be prepared using a known method, and the above-mentioned DNA is prepared by PCR using the primer of the 20 present invention for the immortalization-determining gene. In addition, the probe or primer of the present invention used in Step (1) is preferably labeled with a marker, such as a radioisotope, a fluorescent material, or a chemical luminescent substance. 25 [0063] The amount of the RNA or the RNA derivative found in Step (2) depends on the expression amount of the immortalization-determining gene in the test subject. Accordingly, this amount of RNA or RNA derivative (hereinafter 30 comprehensively referred to as "RNA amount") found in Step (2) is compared with the amount of the corresponding RNA or RNA derivative (hereinafter comprehensively referred to as "comparative RNA amount") in non-immortalized healthy or 3956219_1 (GHMatters) P79759.AU.1 -29 cancer cells to judge the immortalization of the cancer cells of the test subject. More specifically, if the RNA amount of the test subject found in Step (2) is greater than the comparative RNA amount, it is judged that the cancer cells of 5 the test subject are immortalized. In the reverse case, it is judged that the cancer cells of the test subject are not immortalized. [0064] Therefore, in addition to Steps (1) and (2), the 10 immortalized cancer cell determination method of the present invention further includes the following Step (3), and preferably, also Step (4). [00651 (3) a step of comparing the amount of RNA or the RNA 15 derivative (RNA amount) found in Step (2) with the amount of the corresponding RNA or RNA derivative (comparative RNA amount) in a non-immortalized healthy or cancer cell; and (4) a step of judging that the extracted cancer cell of the test subject is immortalized when the RNA amount in Step (2) 20 is higher than the comparative RNA amount, and judging that the extracted cancer cell of the test subject is not immortalized when the RNA amount in Step (2) is not higher than the comparative RNA amount. [00661 25 The RNA amount (comparative RNA amount) of the immortalization-determining gene in a non-immortalized healthy or cancer cell is calculated by first measuring the RNA amount of the immortalization-determining gene in a plurality of non immortalized healthy or cancer cells under the same condition, 30 and then finding a mean or intermediate value of the calculated values. [0067] (111-2) Further, the immortalization of cancer cells can be 3956219_1 (GHMatters) P79759.AU.1 -30 judged based on the quantity of the expression product of the immortalization-determining gene of the present invention, in other words, based on the production quantity of a polypeptide (immortalization-determining polypeptide, hereinafter) encoded 5 by the aforementioned gene. The production quantity of the immortalization-determining polypeptide can be measured using an antibody that recognizes the polypeptide. [00681 The following are immortalization-determining 10 polypeptides that can be used for the present invention that correspond to the aforementioned immortalization-determining genes (1) to (13). [00691 (14) UBE2S polypeptide: a polypeptide encoded by a UBE2S gene 15 (1) having a base sequence represented by the SEQ ID No.1, namely, a polypeptide having an amino acid sequence represented by the SEQ ID No.14. (15) RFC4 polypeptide: a polypeptide encoded by a RFC4 gene (2) having a base sequence represented by the SEQ ID No.2, 20 namely, a polypeptide having an amino acid sequence represented by the SEQ ID No.15. (16) PTGES2 polypeptide: a polypeptide encoded by a PTGES2 gene (3) having a base sequence represented by the SEQ ID No.3, namely, a polypeptide having an amino acid sequence 25 represented by the SEQ ID No.16. (17) MAF1 polypeptide: a polypeptide encoded by a MAF1 gene (4) having a base sequence represented by the SEQ ID No.4, namely, a polypeptide having an amino acid sequence represented by the SEQ ID No.17. 30 (18) ACVR2B polypeptide: a polypeptide encoded by an ACVR2B gene (5) having a base sequence represented by the SEQ ID No.5, namely, a polypeptide having an amino acid sequence represented by the SEQ ID No.18. 3956219_1 (GHMatters) P79759.AU.1 -31 (19) FAM119A polypeptide: a polypeptide encoded by a FAM119A gene (6) having a base sequence represented by the SEQ ID No.6, namely, a polypeptide having an amino acid sequence represented by the SEQ ID No.19. 5 (20) LTB4DH polypeptide: a polypeptide encoded by a LTB4DH gene (7) having a base sequence represented by the SEQ ID No.7, namely, a polypeptide having an amino acid sequence represented by the SEQ ID No.20. (21) DPM2 polypeptide: a polypeptide encoded by a DPM2 gene 10 (8) having a base sequence represented by the SEQ ID No.8, namely, a polypeptide having an amino acid sequence represented by the SEQ ID No.21. (22) SEPX1 polypeptide: a polypeptide encoded by a SEPX1 gene (9) having a base sequence represented by the SEQ ID No.9, 15 namely, a polypeptide having an amino acid sequence represented by the SEQ ID No.22. (23) PSMA3 polypeptide: a polypeptide encoded by a PSMA3 gene (10) having a base sequence represented by the SEQ ID No.10, namely, a polypeptide having an amino acid sequence 20 represented by the SEQ ID No.23. (24) CHCHD3 polypeptide: a polypeptide encoded by a CHCHD3 gene (11) having a base sequence represented by the SEQ ID No.11, namely, a polypeptide having an amino acid sequence represented by the SEQ ID No.24. 25 (25) LSM3 polypeptide: a polypeptide encoded by a LSM3 gene (12) having a base sequence represented by the SEQ ID No.12, namely, a polypeptide having an amino acid sequence represented by the SEQ ID No.25. (26) GTSE1 polypeptide: a polypeptide encoded by a GTSE1 gene 30 (13) having a base sequence represented by the SEQ ID No.13, namely, a polypeptide having an amino acid sequence represented by the SEQ ID No.26. 3956219_1 (GHMatters) P79759.AU.1 -32 [0070] The (14) UBE2S polypeptide is a publicly known polypeptide, and its production is also known, as disclosed in J. Biol. Chem. 267 (22), 15829-15835 (1992). The (15) RFC4 polypeptide 5 is also publicly known as disclosed in Proc. Natl. Acad. Sci. U.S.A. 89 (12), 5211-5215 (1992). Similarly, the polypeptides are publicly known polypeptides, as the (16) PTGES2 polypeptide is disclosed in Biochem. Biophys. Res. Commun. 291 (4), 884-889 (2002); the (18) ACVR2B polypeptide is disclosed 10 in Mol. Cell Biol. 16 (3), 1066-1073 (1996); the (20) LTB4DH polypeptide is disclosed in J. Biol. Chem. 271 (5), 2844-2850 (1996); the (21) DPM2 polypeptide is disclosed in EMBO J. 19 (11), 2475-2482 (2000); the (22) SEPX1 polypeptide is disclosed in J. Biol. Chem. 274 (48), 33888-33897 (1999); the 15 (23) PSMA3 polypeptide is disclosed in Biochem. Biophys. Res. Commun. 207 (1), 318-323 (1995); the (25) LSM3 polypeptide is disclosed in EMBO J. 18 (12), 3451-3462 (1999); and the (26) GTSE1 polypeptide is disclosed in Gene 254 (1-2), 229-236 (2000) 20 [0071] The immortalization-determining polypeptides (14) to (26) may also be prepared by a process comprising cloning the corresponding immortalization-determining genes (1) to (13), ligating the genes into a vector plasmid, transforming the 25 genes into host cells, such as E.coli, culturing the transformed cells, and isolating the polypeptides from the culture. [0072] The antibody used in the present invention is not 30 limited as long as it recognizes the immortalization determining polypeptide, and may be a monoclonal antibody or a polyclonal antibody. The antibody may be an antibody prepared as an antibody against the immortalization-determining 3956219_1 (GHMatters) P79759.AU.1 -33 polypeptide as an immunizing antigen, or an antigen binding antibody with respect to a polypeptide having at least continuous 8 amino acids, preferably 15 amino acids, and more preferably 20 amino acids out of the amino acid sequences 5 forming the immortalization-determining polypeptide. The polypeptide can be generally synthesized by a publicly known method based on the amino acid sequence of the immortalization-determining polypeptide of the present invention or the base sequence that encodes the amino acid. 10 For example, chemical synthesis using an amino acid synthesizer or gene industrial synthesis can be employed. [0073] The antibody of the present invention can be produced by a general method (see, for example, Current protocols in 15 Molecular Biology, edit. Ausubel et al. (1987), Publish. John Wiley and Sons. Section 11.12-11.13). For example, a polyclonal antibody can be produced by using a polypeptide obtained by expressing a polypeptide in E.coli or a synthetic polypeptide that is given the amino acid sequence portions by 20 a general method, immunizing a test animal with the aforementioned polypeptid, and extracting the antibody from a serum obtained from an immune animal. A monoclonal antibody can also be produced from the polypeptide expressed by E.coli or a synthetic polypeptide that is given the amino acid 25 sequence portions by a general method, immunizing a test animal with the aforementioned polypeptide, fusing the spleen cells and myeloma cells extracted from the test animal to synthesize a hybridoma cell, and extracting the antibody from the hybridoma cell. 30 [0074] These antibodies are also included as a component of the aforementioned cancer cell immortalization determining reagent kit for use in judging the immortalization of cancer cells. 3956219_1 (GHMatters) P79759.AU.1 -34 [0075] Specifically, judgment of immortalized cancer cells is carried out with the following Step (1') and Step (2'). (1') a step of mixing a protain-containing fraction containing 5 a polypeptide prepared from a biological sample that has the potential to contain cancer cells obtained from a test subject, with an antibody that recognizes the immortalization determining polypeptide of the present invention; and (2') a step of measuring the amount of polypeptide bonded with 10 the antibody, using the antibody as an index. The amount of polypeptide found in Step (2') depends on the production quantity of the immortalization-determining polypeptide. [0076] 15 In Step (2'), the biological sample can be any sample extracted from the test subject, as long as it has the potential to contain cancer cells. Examples of biological samples include body fluid (blood, urine, etc.), tissues, or extracts thereof, and cultures of the obtained tissues. 20 Extraction of the biological sample from the test subject is performed by an appropriate method according to the type of biological sample or type of cancer. Preparation of the protein-containing fraction (including polypeptide) from the biological sample is performed by an appropriate combination 25 of known differentiation and purification methods. The immortalization-determining polypeptide can be detected by way of various immunological detection methods, such as western blotting, enzyme immunoassay (EIA), radioisotope immunoassay (RIA), luminescence immunoassay, or the like, using the 30 antibody as a probe. [0077] The following explains Steps (1') and (2') for measuring the amount of polypeptide (production quantity of the 3956219_1 (GHMatters) P79759.AU.1 -35 immortalization-determining polypeptide) by way of western blotting. First, an antibody against the immortalization determining polypeptide is mixed as a primary antibody with a protein-containing fraction prepared from a biological sample 5 of the test subject to be bonded with the immortalization determining polypeptide contained in the protein-containing fraction. Next, a secondary antibody labeled with a radioisotope, a fluorescent material, or a chemical luminescent substance is bonded with the primary antibody. 10 Then, the amount of immortalization-determining polypeptide is measured based on the signal that derives from the marker of the secondary antibody. Detection of the signal can be carried out by an appropriate known method using, for example, a radiation detector, or a fluorescence detector. 15 [0078] The immortalization of the cancer cells of the test object can be judged by comparing the obtained amount of polypeptide (production quantity of the immortalization determining polypeptide) in the test subject in Step (2') with 20 the amount of comparative immortalization-determining polypeptide (comparative production quantity) in a non immortalized healthy or cancer cell, and finding the difference level. More specifically, if the obtained amount of polypeptide (production quantity of the immortalization 25 determining polypeptide) in the test subject in Step (2') is greater than the amount of comparative polypeptide (comparative production quantity), it is judged that the cancer cells of the test subject are immortalized. In the reverse case, it is judged that the cancer cells of the test 30 subject are not immortalized. [0079] Accordingly, in addition to the aforementioned Steps (1') and (2'), the immortalized cancer cell determination 3956219_1 (GHMatters) P79759.AU.1 -36 method of the present invention includes the following Step (3'), and preferably, also Step (4'). (3') a step of comparing the amount of polypeptide found in Step (2') with the amount (comparative polypeptide amount) of 5 the corresponding polypeptide in a non-immortalized healthy or cancer cell; and (4') a step of judging that the extracted cancer cell of the test subject is immortalized when the amount of polypeptide found in Step (2') is higher than the comparative polypeptide 10 amount, and judging that the extracted cancer cell of the test subject is not immortalized when the polypeptide amount is not higher than the comparative polypeptide amount. [00801 The production quantity of the immortalization 15 determining polypeptide in a non-immortalized healthy or cancer cell is calculated by first measuring the production quantity of the immortalization-determining polypeptide in a plurality of non-immortalized healthy or cancer cells under the same condition, and then finding a mean or intermediate 20 value of the calculated values. [0081] (IV) A method for screening immortalized cancer cell growth inhibitor (IV-1) As shown in the Examples, the immortalization 25 determining genes ((1) to (13)) according to the present invention exhibit high expression specifically in immortalized cancer cells. Further, by suppressing the expression using siRNA of the immortalization-determining genes, proliferation of the immortalized cancer cells is suppressed. This 30 indicates that the substance that suppresses the expression of the immortalization-determining genes ((1) to (13)) can serve as an immortalized cancer cell growth inhibitor (anticancer drug). Therefore, by using the expression suppression of the 3956219_1 (GHMatters) P79759.AU.1 -37 immortalization-determining genes ((1) to (13)) as an index, the substance that suppresses proliferation of the immortalized cancer cells can be screened. [0082] 5 Accordingly, the present invention provides a method for screening immortalized cancer cell growth inhibitors using the expression suppression of the immortalization-determining genes ((1) to (13)) as an index. [00831 10 The present method may include the following Steps (A) to (D). (A) a step of bringing a test material into contact with a cell that can express one of the immortalization-determining genes (1) to (13); 15 (B) a step of measuring the expression amount of the immortalization-determining gene in the cell brought into contact with the test material; (C) a step of comparing the expression amount of the immortalization-determining gene found in Step (B) with the 20 expression amount (comparative expression amount) of the immortalization-determining gene in a cell not in contact with the test material; and (D) a step of selecting the test material as a substance for inhibiting the proliferation of the immortalized cancer cells 25 when the expression amount found in Step (B) is lower than the comparative expression amount. [0084] The cell used in the present invention can derive from any kind of cell as long as the cell can express at least one 30 of the immortalization-determining genes (1) to (13). Examples of organs from which the cell used may derive include lung, stomach, colon, rectum, liver, gallbladder, bile duct, pancreas, kidney, bladder, prostate gland, womb, marrow, lymph 3956219_1 (GHMatters) P79759.AU.1 -38 gland and blood. The cell may derive from mammals or birds, preferably mammals, and more preferably humans. The expression of the immortalization-determining gene may be endogenous or exogenous. 5 [00851 The test material is not limited and may be nucleic acid (including polynucleotides), a peptide (including polypeptides), an organic compound, or an inorganic compound. The screening is carried out by bringing a test material or a 10 sample containing the test material (test sample) into contact with a cell that can express the immortalization-determining gene. Examples of the test sample include cell extracts, expression products from a gene library, and extracts of natural vegetable or animal-origin products. 15 [00861 In the screening, the process of bringing the test material into contact with the cell is not limited as long as it does not kill the cell and does not inhibit the expression of the immortalization-determining gene in the cell. 20 [0087] In Steps (B) and (C), the expression amount of the immortalization-determining gene can be found by measuring the amount of mRNA of the immortalization-determining gene or its derivative cDNA or double-strand DNA by northern blotting or 25 RT-PCR, using the aforementioned probe or primer of the present invention. Further, the amount of the immortalization-determining polypeptide as an expression product of the immortalization-determining gene may be used to find the expression amount of the immortalization-determining 30 gene in Steps (B) and (C) . The amount of the immortalization determining polypeptide can be found through various immunological detection methods, such as western blotting, enzyme immunoassay (EIA), radioisotope immunoassay (RIA), 3956219_1 (GHMatters) P79759.AU.1 -39 luminescence immunoassay, or the like, using an antibody against the immortalization-determining polypeptide. [00881 In Step (C), the substance that inhibits proliferation 5 of the immortalized cancer cells can be screened by comparing the expression amount of the immortalization-determining gene measured in Step (B) with the expression amount of the immortalization-determining gene (comparative expression amount) in a cell not in contact with the test material. More 10 specifically, when the expression amount of the immortalization-determining gene found in Step (B) is lower than the comparative expression amount, the test material can be selected as a substance for inhibiting the proliferation of the immortalized cancer cell. 15 [00891 (IV-2) Activity inhibition of the immortalization-determining polypeptides ((14) to (26)), which are the expression products of the immortalization-determining genes ((1) to (13)) of the present invention also constitutes an index to screen the 20 immortalized cancer cell growth inhibitor. For example, the (14) UBE2S polypeptide is known to have a ubiquitin activator (E2) (J. Biol. Chem. 267 (22) , 15829-15835 (1992) ); The (16) PTGES2 polypeptide is known to have an activity to convert prostaglandin H2 to prostaglandin E2 (Biochem. Biophys. Res. 25 Commun. 291 (4), 884-889 (2002)); the (18) ACVR2B polypeptide is a transmembrane receptor, and has a Ser/Thr kinase activity in the intercellular domain (Mol. Cell Biol. 16 (3), 1066-1073 (1996)); the (20) LTB4DH polypeptide has an activity to convert leukotriene B4 to 12-oxo-leukotriene B4 (J. Biol. Chem. 30 271 (5), 2844-2850 (1996)); and the (22) SEPX1 polypeptide has a methionine sulfoxide reducing activity (Mol. Biol. Cell 15 (3), 1055-1064 (2004)); therefore, inhibitions of these activities of the immortalization-determining polypeptides is 3956219_1 (GHMatters) P79759.AU.1 -40 particularly useful as indices to screen the immortalized cancer cell growth inhibitor. [00901 More specifically, by carrying out the following Steps 5 (A') to (D'), a substance for suppressing the proliferation of the immortalized cancer cells can be screened. (A') a step of bringing a test material into contact with one of the immortalization-determining polypeptides (14) to (26); (B') a step of measuring the activity of the immortalization 10 determining polypeptide in contact with the test material; (C') a step of comparing the activity of the immortalization determining polypeptide measured in Step (B') with the activity (comparative activity) of the immortalization determining polypeptide in an aqueous solution, a cell, or a 15 cell fraction that is not in contact with the test material; and (D') a step of selecting the test material as a substance for inhibiting the proliferation of the immortalized cancer cells when the activity found in Step (B') is lower than the 20 comparative activity. [0091] The screening uses the activity of the immortalization determining polypeptide as an index, and may be carried out with respect to any object that contains or may contain one of 25 the immortalization-determining polypeptides (14) to (26) (preferably (14), (16), (18), (20) or (22)). An appropriate object is selected according to the desired function (activity) of the immortalization-determining polypeptide. Examples of objects subjected to screening include an aqueous 30 solution containing one of the immortalization-determining polypeptides (14) to (26) (preferably (14), (16), (18), (20) or (22)); a cell that can express one of the immortalization determining genes (1) to (13) (preferably (1), (3), (5), (7) 3956219_1 (GHMatters) P79759.AU.1 -41 or (9)); or a cell fraction prepared from the aforementioned cell. The aqueous solution is not particularly limited as long as it contains an immortalization-determining polypeptide. In addition to a general aqueous solution, a cell solution, a 5 nuclear extraction, or a liquid culture supernatant may be used. The cell may be endogenous or exogenous, and may be any cell that can express one of the immortalization-determining genes. The cell fraction designates a fraction that derives from the aforementioned cell, such as a cell membrane fraction, 10 a cytoplasmic fraction, a cell nucleus fraction, or the like. [0092] The same cell and test material as those for the previously described screening can be used for this screening process. 15 [00931 Measurement of the ubiquitin activation capability of the UBE2S polypeptide (14) in Step (B') can be carried out by a known method. For example, "J. Biol. Chem. 267 (22), 15829 15835 (1992)" discloses a method of performing ubiquitin 20 activation reaction of the UBE2S polypeptide in a system containing ubiquitin, a ubiquitin activating enzyme (El), and UBE2S polypeptide, and measuring the amount of ubiquitin bonded to the UBE2S polypeptide. Measurement of the ubiquitin amount may be performed by a known method. For example, the 25 reaction is performed using ubiquitin labeled with a radioactive material or enzyme, and the amount of the marker is measured (J. Biol. Chem. 267 (22), 15829-15835 (1992), J. Biol. Chem. 279 (51), 52970-52977 (2004)). Alternatively, measurement can be performed by detecting ubiquitin using an 30 anti-ubiquitin antibody (J. Biol. Chem. 279 (51), 52970-52977 (2004)) . The ubiquitin and ubiquitin activating enzyme (El) may be a marketed commodity, or may be obtained by a known protein synthesis process. 3956219_1 (GHMatters) P79759.AU.1 -42 [0094] Measurement of the prostaglandin E2 synthesis activity of the PTGES2 polypeptide (16) in Step (B') may be performed using a known method. For example, as disclosed in "Biochem. 5 Biophys. Res. Commun. 291 (4), 884-889 (2002)", the production amount of the prostaglandin E2 can be measured by performing a prostaglandin E2 conversion reaction using PTGES2 polypeptide in a system containing PTGES2 polypeptide and prostaglandin H2. The amount of the prostaglandin E2 can be measured using a 10 known method. For example, according to "Proc. Natl. Acad. Sci. U.S.A. 96 (13), 7220-7225 (1999))", the reaction is performed using prostaglandin H2 labeled with a radioactive material or enzyme, and then the amount of the marker is measured to find the production quantity of the prostaglandin 15 E2. Alternatively, the measurement can be performed by using an anti-prostaglandin E2 antibody (J. Dairy. Sci. 87 (7), 2197-2210 (2004)). The prostaglandin H2 may be a marketed commodity, or may be obtained by a known synthesis process. [00951 20 Measurement of the Ser/Thr kinase activity of the ACVR2B polypeptide (18) in Step (B') may be performed using a known method. For example, as disclosed in "Mol. Cell Biol. 16 (3), 1066-1073 (1996)", the Ser/Thr kinase activity can be measured by performing a kinase reaction in a system containing ACVR2B 25 polypeptide in the presence of a substrate and ATP, and then measuring the phosphorylation quantity of the substrate. The phosphorylation quantity of the substrate may be measured by a known method. For example, the phosphorylation quantity may be measured by measuring radioactivity using y P-ATP or y P 30 ATP as a tracer (Mol. Cell Biol. 16 (3), 1066-1073 (1996)). Alternatively, the phosphorylation quantity may be measured by performing a phosphorylation reaction using a substrate labeled with a fluorescent material or biotin, and measuring 3956219_1 (GHMatters) P79759.AU.1 -43 the quantity of the phosphorylation marker. Examples of substrates include ACVR2B polypeptide, and specific substrates and peptides. [00961 5 Measurement of the leukotriene B4 conversion activity of the LTB4DH polypeptide (20) in Step (B') may be performed using a known method. For example, as disclosed in "J. Biol. Chem. 271 (5), 2844-2850 (1996)", the leukotriene B4 conversion activity can be measured by performing a 10 leukotriene B4 conversion reaction using LTB4DH polypeptide in a system containing LTB4DH polypeptide and leukotriene B4, and then measuring the production quantity of the 12-oxo leukotriene B4. The production quantity of the 12-oxo leukotriene B4 may be measured by a known method, such as HPLC. 15 The leukotriene B4 may be a marketed commodity, or may be obtained by a known chemical synthesis process. [0097] Measurement of the methionine sulfoxide reducing activity of the SEPX1 polypeptide (22) in Step (B') may be 20 performed using a known method. For example, as disclosed in "Mol. Biol. Cell 15 (3), 1055-1064 (2004)", the methionine sulfoxide reducing activity can be measured by performing a methionine sulfoxide reducing reaction using SEPX1 polypeptide in a system containing SEPX1 polypeptide and methionine 25 sulfoxide, and then measuring the production quantity of the methionine. The production quantity of the methionine may be measured by a known method, such as HPLC. The methionine sulfoxide may be a marketed commodity, or may be obtained by a known chemical synthesis process. 30 [00981 In Steps (C') and (D'), the substance that inhibits the proliferation of the immortalized cancer cells can be screened by comparing the measured activity of the immortalization 3956219_1 (GHMatters) P79759.AU.1 -44 determining polypeptide in Step (B') with the comparative activity. More specifically, when the measured activity of the immortalization-determining polypeptide is lower than the comparative activity, the test material is determined to be a 5 substance for inhibiting the proliferation of the immortalized cancer cell. [00991 As explained in the Examples, each of the antisence polynucleotides (siRNA) (SEQ ID No.s 27 to 39) shown in Table 10 2 hybridizes with one of the immortalization-determining genes of the present invention in a cancer cell to suppress the expression of the immortalization-determining gene, thereby suppressing the proliferation of the immortalized cancer cells. Therefore, the antisence polynucleotide (siRNA) can be used as 15 an immortalized cancer cell growth inhibitor. Accordingly, the present invention provides an immortalized cancer cell growth inhibitor containing the antisence polynucleotide as an active ingredient. [0100] 20 The antisence polynucleotide is formed of a polynucleotide of at least 15 bases that specifically hybridizes with a polynucleotide having a continuous base sequence of at least 15 bases within a base sequence of the immortalization-determining genes (1) to (13). The 25 polynucleotide preferably has a base sequence complementary to the continuous base sequence of at least 15 bases in one of the immortalization-determining genes (1) to (13); however, as long as a specific hybridization is possible and thereby the expression of the immortalization-determining gene is 30 suppressed, it is not required to be totally complementary. For example, the base sequence of the polynucleotide may have an identity of 70%, preferably not less than 80%, more preferably not less than 90%, yet more preferably not less 3956219_1 (GHMatters) P79759.AU.1 -45 than 95%, and still more preferably not less than 98%, with respect to the complementary sequence of the immortalization determining gene; and the polynucleotide may hybridize with RNA of the immortalization-determining gene to suppress the 5 expression of the immortalization-determining gene. The antisence polynucleotide of the present invention preferably has 15 to 1,000 bases, more preferably 15 to 500 bases, and yet more preferably 16 to 30 bases. [0101] 10 The antisence polynucleotide of the present invention preferably has a base sequence represented by one of SEQ ID No.s 27 to 39, and more preferably a double-strand RNA having one of the base sequences. [0102] 15 The antisence polynucleotide of the present invention may be modified with a known technique to improve stability and cell permeability. For example, a phosphoric residue of each nucleotide may be substituted with a chemically modified phosphoric residue, such as phosphorothioate, methyl 20 phosphonate, or phosphorodithioate, to prevent decomposition by a hydrolase such as nuclease. [0103] The form of the antisence polynucleotide of the present invention is not limited and may be single-strand DNA, single 25 strand RNA, double-strand DNA, double-strand RNA or DNA:RNA hybrid. [0104] Generally, the antisence polynucleotide of the present invention may be synthesized using a known method, such as 30 chemical synthesis using a synthesizer. [0105] The antisence polynucleotide of the present invention is introduceable into cancer cells of a patient using a virus 3956219_1 (GHMatters) P79759.AU.1 -46 vector, such as a retrovirus vector, adenovirus vector, or adeno-associated virus vector, or a non-virus vector such as liposome, through an ex vivo process or an in vivo process, thereby suitably serving as an anticancer treatment. 5 Accordingly, the present invention includes an anticancer treatment method comprising the step of administering an immortalized cancer cell growth inhibitor containing the antisence polynucleotide as an active ingredient to a patient. [0106] 10 The immortalized cancer cell growth inhibitor of the present invention contains the aforementioned antisence polynucleotide as an active ingredient, and may also contain a stabilizer, a suspension, a freezing mixture, a buffer solution, a solvent, or the like insofar as the cell 15 proliferation suppression effect of the inhibitor is not impaired. The dosage and administration schedule of the immortalized cancer cell growth inhibitor of the present invention to a cancer patient can be suitably determined by a person having skill in the art according to the type of 20 disease, patient's age, weight, etc. Examples of administration schedules include a 3-week cycle of intravenous administration in which a consecutive 2 to 3-week administration of the antisence polynucleotide is carried out with a dosage of 2 to 10 mg/kg per day; a 1-week cycle of 25 intravenous administration in which consecutive 5-day administration of the antisence polynucleotide is carried out with a dosage of 80 to 120 mg/m 2 per day; and a 4-week cycle of intravenous administration in which a consecutive 3-week administration of the antisence polynucleotide is carried out 30 with a dosage of 80 to 120 mg/m 2 per day. 3956219_1 (GHMatters) P79759.AU.1 -47 EXAMPLE [0107] The present invention is more specifically explained below in reference to examples. The present invention is, 5 however, not limited to those examples. [0108] Example 1 Identification of immortalization-determining gene 1. Preparation of total RNA from human tissue sample, human 10 cancer cell strain, and human nonneoplastic culture cell TM Using an RNeasy Mini kit (Qiagen), total RNAs were extracted from nine kinds of lung cancer cell strains, 21 kinds of esophagus cancer cell strains, nine kinds of digestive system cancers, various other cancer cell strains (gastric cancer, 15 colon cancer, head neck cancer, leukemia), two kinds of nonneoplastic esophagus epithelial cells, and two kinds of normal respiratory epithelia, according to the attached protocol. The extracted total RNAs were preserved at -80'C. [0109] 20 Further, total RNAs were also extracted from eleven kinds of breast cancer cell strains, ten kinds of ovary cancer cell strains, ten kinds of pancreas cancer cell strains, one kind of nonneoplastic immortalization mammary gland epithelia, one kind of nonneoplastic mammary gland epithelia, ten sets of 25 pancreatic cancer tissue and non-cancer pancreas tissue of the same pancreatic cancer patient, the primary focus and three metastasis portions of lung cancer tissue of the same non small cell lung cancer patient. The obtained total RNAs were preserved. The total RNAs were examined to ensure high 30 quality, with clear 18S and 28S rRNA peaks using a 2100 Bioanalyzer (Agilent Technologies) and RNA LabChip (Agilent Technologies), before they were subjected to a microarray assay. 3956219_1 (GHMatters) P79759.AU.1 -48 [0110] 2. Microarray assay Using the extracted total RNAs, an exhaustive gene expression assay was carried out by way of a microarray. The 5 microarray used a CodeLink UniSet Human 20K I Bioarray (19881 probe), and comprised (1) a synthesis of cDNA from total RNA, (2) a synthesis of labeled cRNA from the cDNA, (3) a fragmentation process of the labeled cRNA, (4) a hybridization of fragment cRNA and microarray, (5) staining of a microarray, 10 (6) scanning of a microarray, and (7) a gene expression assay. [0111] (1) Synthesis of cDNA from total RNA Using a CodeLink Expression Assay Reagent Kit (GE Healthcare Bio Science), a first-strand cDNA was synthesized 15 according to the protocol. More specifically, 1 pg each of the total RNAs obtained in section 1 were adjusted to 10 pl with nuclease-free water, mixed with 1 pl of a bacterial control mRNA diluent solution and 1 pl of T7 oligo (dT) primer, both contained in the kit. The total 12 pl of liquid was 20 heated at 700C for 10 minutes, followed by 3 minutes rapid cooling on ice. On the ice, the liquid was mixed with 2 pl of 10 x first-strand buffer, 4 pl of 5-mM dNTP Mix, 1 pl of RNase inhibitor, and 1 pl of reverse transcriptase (200 U/pl), all contained in the kit. The total 20 pl of liquid was heated at 25 420C for two hours. [0112] Subsequently, according to the protocol, the RNA in the RNA-DNA hybrid was decomposed, and the RNA strand was substituted with a DNA strand, thereby synthesizing a second 30 strand cDNA (double-strand cDNA). More specifically, 63 pl of nuclease-free water, 10 x second-strand buffer (10 pl), 5-mM dNTP mix (4 pl), DNA polymerase mix (2 pl:10 U/pl), 1 pl of RNase H, all contained in the kit, were added to the 20 pl of 3956219_1 (GHMatters) P79759.AU.1 -49 first-strand cDNA reaction solution. The total 100 pl of liquid was heated at 160C for two hours. [0113] After the reaction, the synthesized double-strand cDNA 5 was purified using a QIA quick PCR purification Kit (QIAGEN) according to the attached protocol. More specifically, 100 Pl of the cDNA solution was mixed with 500 pl of buffer PB contained in the kit, and the mixed liquid was placed in a QIA quick spin column set in a 2-ml centrifugal tube and subjected 10 to centrifugation for 50 seconds at 13,000 rpm. After the elution liquid was removed, the QIA quick spin column was set again, 700 pl of buffer PE contained in the kit was added thereto, and 13,000 rpm centrifugation was performed for 1 minute. The elution liquid was removed, the QIA quick spin 15 column was set again, and still another centrifugation was performed at 13,000 rpm for 1 minute so as to completely remove the buffer PE. The QIA quick spin column was set in a new 1.5-ml tube, and 30 pl of nuclease-free water was directly added onto the membrane in the QIA quick spin column, allowed 20 to stand for 1 minute, and followed by 13,000-rpm centrifugation for 1 minute. This process was performed twice (60 pl was used in total). Then, the cDNA solution was concentrated to less than 9.5 pl using a vacuum dryer, and adjusted by adding nuclease-free water to 9.5 pl. 25 [0114] (2) Synthesis of labeled-cRNA from cDNA Subsequently, according to the protocol of a CodeLink Expression Assay Reagent Kit (GE Healthcare Bio Science), an in vitro transcription (IVT) reaction was performed in the 30 presence of a biotin-labeled nucleotide to synthesize a cRNA. More specifically, 4.0 pl of a 10 x T7 reaction buffer, 4.0 pl of a T7 ATP solution, 4.0 pl of a T7 GTP solution, 4.0 pl of a T7 CTP solution, and 3.0 pl of a T7 UTP solution, all 3956219_1 (GHMatters) P79759.AU.1 -50 contained in the kit, were mixed. After further adding 7.5 pl of 10-mM biotin-11-UTP (Perkin Elmer Corporation), the total 26.5 pl of liquid was added to the 9.5 pl of cDNA solution prepared in the foregoing process (1). Further, 4.0 pl of a 5 10 x T7 Enzyme Mix contained in the kit was added, and the total 40.0 pl of liquid was mixed well and heated in a vapor phase at 370C for 14 hours. After the reaction, the synthesized cRNA was purified using an RNeasy Mini Kit(QIAGEN) according to the attached protocol. More specifically, 60 pl 10 of nuclease-free water was added to the IVT reaction solution (40 pl), and 350 pl of buffer RLT contained in the kit and 250 pl of 100% ethanol was added and mixed well, and the total 700 pl of mixed liquid was placed in an RNeasy mini spin column to be subjected to centrifugation for 15 seconds at 12,000 rpm. 15 The RNeasy mini spin column was set in a new 2-ml centrifugal tube, 500 pl of buffer RPE contained in the kit was added to the column, and another 12,000-rpm centrifugation was performed for 15 seconds. This process was performed twice. After the elution liquid was removed, the RNeasy mini spin 20 column was set in the 2-ml centrifugal tube, and 12,000 rpm centrifugation was performed for 2 minutes to dry the membrane in the column. Thereafter, the RNeasy mini spin column was set in a new 1.5-ml tube, and 50 pl of nuclease-free water was directly added onto the membrane, allowed to stand for 10 25 minute at room temperature, and followed by 12,000-rpm centrifugation for 1 minute. This process was performed twice (100 pl was used in total). [0115] The sample was mixed well, and dispensed into a 2 -pl 30 portion for cRNA quality check using an Agilent 2100 Bioanalyzer and a 2 -pl portion diluted 50-fold with sterile distilled water for cRNA quantitative determination; the rest was preserved at -80'C. For the quantitative determination, 3956219_1 (GHMatters) P79759.AU.1 -51 the absorbency of the 50-fold diluted solution was measured with respect to 260 nm and 280 nm, and the cRNA concentration was determined. The absorbency ratio of 260 nm to 280 nm was confirmed as 1.8 or greater. When the RNA concentration was 5 0.5 pg/pl or less, the sample was concentrated using a vacuum dryer. The cRNA quality check was performed by electrophoresis using an Agilent 2100 Bioanalyzer and RNA LabChip according to the attached protocol, confirming that the smear peak had at least 500 bases. 10 [0116] (3) Fragmentation of labeled cRNA Subsequently, according to the protocol of the CodeLink Expression Assay Reagent Kit (GE Healthcare Bio Science), the cRNA was fragmented into about 100 to 200 bases. More 15 specifically, nuclease-free water was added so that the 10 pg of cRNA became 20 pl; then, 5 pl of 5 x fragmentation buffer contained in the kit was added. After heating at 940C for 20 minutes, the liquid was rapidly cooled on ice. 78 pl of hybridization buffer A, 130 pl of hybridization buffer B, 27 20 pl of nuclease-free water, all contained in the kit, were added to the 25 pl of solution containing 10 pg of cRNA fragments, preparing a hybridization solution of 260 pl in total. After vortexing at maximum speed for 5 seconds and spinning-down, the sample was heated at 90'C for 5 minutes to 25 denaturate the cRNA by heat, followed by cooling on ice. [0117] (4) Hybridization of cRNA fragment and microarray Using a CodeLink Shaker Kit (GE Healthcare Bio Science) and a CodeLink Innova shaker, hybridization was performed 30 according to the protocol. More specifically, a CodeLink uniSet human 20K I bioarray was set in the 12-slide shaker tray contained in the kit. The hybridization solution prepared in the foregoing process (3) was vortexed at maximum 3956219_1 (GHMatters) P79759.AU.1 -52 speed for 5 seconds and spinned down. The 250 pl of hybridization solution was injected to a right-bottom hole of the sealing chamber of the array, and the hole was covered with a sealing strip (sticker) attached to the array. The 5 shaker tray having an array thereon was placed in the CodeLink Innova shaker, and heated at 370C for 18 hours while being rotated at 300 rpm. [0118] (5) Staining of microarray 10 Using a CodeLink Parallel Processing Kit (GE Healthcare Bio Science), the array was stained and washed according to the protocol. More specifically, the sealing chamber was removed from the hybridized array, 13 ml of 0.75 x TNT buffer (0.1M Tris-HCl (pH 7.6), 0.15M NaCl, 0.05% Tween 20) was added 15 at room temperature, and the resulting liquid was divided into the slots of a medium reagent reservoir with a bioarray rack contained in the kit. The rack was moved up and down several times to shake off extra hybridization solution. The bioarray rack was then shifted to a large reagent reservoir filled with 20 240 ml of 0.75 x TNT buffer heated to 460C. The bioarray rack was heated to 460C for an hour. [0119] As a staining fluid, for each array, 6.8 pl of Streptavidin-Cy5 liquid dissolved by nuclease-free water to 1 25 mg/ml was diluted 500-fold using 3393.2 pl of TNB buffer (0.1 M Tris-HCl(pH 7.6), 0.15 M NaCl, 0.5 % TSA Blocking Reagent (Perkin Elmer Corporation)) at room temperature. The total 3.4 ml was supplied to fill up the slots of a small reagent reservoir contained in the kit. The bioarray rack holding the 30 array was shifted to the small reagent reservoir, blocked from light with aluminum or the like, and subjected to staining for 30 minutes at room temperature (230C ±2 0C). 3956219_1 (GHMatters) P79759.AU.1 -53 [0120] After staining, the bioarray rack was shifted to a large reagent reservoir filled with 240 ml of TNT buffer (room temperature), moved up and down several times and allowed to 5 stand for 5 minutes at room temperature. The rack was then shifted to a large reagent reservoir filled with new TNT buffer (room temperature), moved up and down several times and allowed to stand for 5 minutes at room temperature. This washing process was repeated four times. Finally, the rack 10 was washed with 240 ml of 0.05% Tween 20 solution by being moved up and down for five seconds. This process was repeated twice. The bioarray rack was set in a dried medium reagent reservoir, followed by 3 minutes of centrifugation at room temperature, 600 x g. 15 [0121] (6) Scanning of microarray Each of the stained arrays was scanned by an Agilent G2565 scanner (Agilent), to be saved a staining pattern as TIFF image. Each TIFF image was processed by CodeLink 20 expression analysis software, thereby digitizing a signal strength for each gene spot on the array. [0122] (7) Gene expression assay The signal strength data thus obtained was normalized 25 using GeneSpring GX (Agilent Technologies) microarray gene expression assay software, and the data was then assayed. Specifically, the background signal was subtracted from the spot signal. Values less than 0.01 were equalized to 0.01, and each value was divided by the intermediate value of all 30 spot signals so as to find a standardized relative expression amount of the gene. Genes whose relative expression amount was higher universally in the immortalized cancer cell strains (FIG. 1, lower right) than a healthy cell (FIG. 1, upper left) 3956219_1 (GHMatters) P79759.AU.1 -54 were discriminated in the following manner. Genes that exhibited enhanced expression universally in various organs appeared to be genes involved in cancer cell immortalization (FIG. 1, large arrow pointing to the right), rather than genes 5 (FIG. 1, downward arrow) involved in canceration of healthy cells (FIG. 1, upper left). [0123] Screened as the first group was any gene in which at least 8 out of 9 kinds of lung cancer cell strains exhibited 10 expression in a quantity of two times or higher than the intermediate value of two normal respiratory epithelia, any gene in which at least 19 out of 21 kinds of esophagus cancer cell strains exhibited expression in a quantity of two times or higher than the intermediate value of two nonneoplastic 15 esophagus epithelia, and any gene in which at least 8 out of 9 digestive cancers, or various other cancer cell strains (gastric cancer, colorectal cancer, head and neck cancer, leukemia) exhibited expression in a quantity of two times or higher than the intermediate value of the four kinds of 20 nonneoplastic epithelia (two kinds of respiratory epithelia and two kinds of esophagus epithelia). As a result, fifty-one genes were screened (FIG. 2, upper left). As the second group, screened was any gene in which the mean value of the expression levels of the three groups of cancer cell strains 25 of different organs was two times or higher than the mean value of the corresponding epithelia (note that, the esophagus cancer cell strains used for this screening based on the mean value correspond to the seven kinds asseyed first), and in which the expression level of the metastasis lung cancer 30 tissue consisting of immortalization lung cancer cells was two times or higher than the mean value of the primary focus tissue and metastasis tissue consisting of non-immortalization lung cancer cells of the same patient. As a result, 80 genes 3956219_1 (GHMatters) P79759.AU.1 -55 were extracted (FIG. 2, upper right). Among the two screened groups, seven genes were common. [0124] It is a known fact that cancer cell strains are all 5 immortalized. For each of the immortalization/non immortalization lung cancer tissues used in the experiments, it was confirmed that the primary focus (FIG. 3, "D2Pr") and hepatic metastasis focus (FIG. 3, "D5M3") of the same patient were not immortalized (telomerase activitation: negative; 10 telomere length: reduced; hTERT protein expression: not observed), and that one of the lymph node metastasis focuses (FIG. 3, "D4M2") substantially consisted only of immortalized cells (high telomerase activation, extended telomere length, hTERT protein expression was observed in almost all cells) and 15 the other metastasis focus (FIG. 3, "D3M1") consisted of both immortalized cells and non-immortalization cells (low telomerase activation; hTERT protein expression cells were observed among the non-expression cells). These characteristics were confirmed by assaying telomerase 20 activation (Hiyama K et al., J Natl Cancer Inst 87: 895-902, 1995, Case G), telomere length (Hiyama K et al., Oncogene 10: 937-44, 1995, Case 92-D), and hTERT protein in situ expression (Hiyama E et al., Neoplasia 3: 17-26, 2001, Fig 6A, B). [0125] 25 For further refinement, a gene that exhibits high expression universally in 11 cell strains of breast cancer, 10 cell strains of ovarian cancer, and 10 cell strains of pancreatic cancer was screened. Finally, in total, the thirteen genes: (1) ubiquitin-conjugating enzyme E2S (UBE2S), 30 (2) replication factor C (activator 1) 4, 37kDa(RFC4), (3) prostaglandin E synthase 2, (PTGES2), (4) MAF1 homolog (S. cerevisiae) (MAF1), (5) activin A receptor, type IIB(ACVR2B), (6) family with sequence similarity 119, member A (FAM119A), 3956219_1 (GHMatters) P79759.AU.1 -56 (7) leukotriene B4 12-hydroxydehydrogenase (LTB4DH), (8) dolichyl-phosphate mannosyltransferase polypeptide 2, regulatory subunit (DPM2), (9) selenoprotein X, 1(SEPX1), (10) proteasome (prosome, macropain) subunit, alpha type, 3 (PSMA3), 5 (11) coiled-coil-helix-coiled-coil-helix domain containing 3 (CHCHD3), (12) LSM3 homolog, U6 small nuclear RNA associated (S. cerevisiae) (LSM3), and (13) G-2 and S-phase expressed 1(GTSE1), were found as genes that exhibit higher expression universally in most lung cancer cell strains, esophagus cancer 10 cell strains, digestive cancer cell strains, breast cancer cell strains, ovarian cancer cell strains, pancreatic cancer cell strains and various other cancer cell strains than mortal nonneoplastic cells; exhibit higher expression in a telomerase-positive lung cancer metastasis tissue 15 (immortalized cancer cells) than in a telomerase-negative lung cancer metastasis tissue and primary tissue (non-immortalized cancer cells) of the same patient; and exhibit higher expression in pancreatic cancer cell strains consists only of immortalized cells than in a pancreatic cancer tissue 20 containing both immortalized cells and non-immortalized cells (FIG. 3). The pancreatic cancer tissue used in this experiment showed a higher expression of full length mRNA of the telomerase-coding gene TERT than in the healthy pancreatic tissue of the same patient. However, since the expression was 25 evidently lower compared with the immortalized pancreatic cancer cell strains, it is assumed that the tissue contained non-immortalized cells. [0126] As shown in FIGS. 3 to 15, the foregoing thirteen genes 30 have the following characteristics. (1) each gene exhibits more enhanced expression in immortalization cells (solid bar in FIGS. 3 to 15, human cancer derived cell strains except for MCF-12A, SV11e, SV11 3956219_1 (GHMatters) P79759.AU.1 -57 106) than in nonneoplastic mortal cells (open bar in FIGS. 3 to 15); (2) each gene exhibits more enhanced expression in immortalized cancer cells derived human cancer (solid bar in 5 FIGS. 3 to 15, except for MCF-12A, SV11e, SV11-106) than finite life cancer cells (diagonal lined bar in FIGS. 3 to 15, except for SV12e, SV12-72); and (3) its expression is less enhanced in nonneoplastic telomerase expression life-extension cells obtained by 10 introducing a telomerase-coding gene TERT into healthy lung fibroblasts (diamond-shaped dotted bars in FIGS. 3 to 15; TERT6e, TERT6-85) than in the parent cells (TIG-1). These genes are highly expressed specifically in telomerase-positive immortalized cancer cells. This shows that these genes serve 15 to determine the immortalization of cancer cells (immortalization-determining gene). [0127] Moreover, in the immortalization transformed cells obtained by introducing genes encoding a telomerase-coding 20 gene TERT and SV40 early antigen into healthy lung fibroblasts (FIGS. 3 to 15, SV11e, SV11-106: colony formation and 300 PDL or greater passage capability of passage were confirmed using colony formation assay with soft agar), the expression was enhanced except for MAF1, LTB4DH, than in the parent cells 25 (TIG-1) or nonneoplastic life-extension cells (TERT6e, TERT6 85: absence of colony formation and cessation of cell proliferation at 100PDL or less were confirmed using colony formation assay with soft agar). This is presumably because the cells transformed in vitro are not always equal to human 30 cancer cells. 3956219_1 (GHMatters) P79759.AU.1 -58 [0128] Example 2 Suppression of cancer cell proliferation by siRNA (small interfering RNA) of immortalization-determining gene 5 To analyze how the thirteen kinds of immortalization determining genes identified in Example 1 relate to cancer cell proliferation, siRNAs specified according to the respective gene sequences were designed and created. They were introduced into three kinds of cancer cell strains (HeLa: 10 uterine cervix cancer, KYSE150: esophagus cancer, and HCC50: colon cancer). With these samples, the suppression of mRNA expression of an immortalization-determining gene, and the effect on cell proliferation at 96 hours after introduction were observed. 15 [0129] (1) Designing and creation of immortalization-determining gene sequence specific siRNA (small interfering RNA) In each of the thirteen immortalization-determining genes, two or four kinds of specific siRNA sequences were 20 determined, and Double-strand siRNAs each formed of a sense strand and an antisense strand was purchased from Qiagen and Japan Bio Service. Among the created siRNAs sequences, only the sense strands are shown in Tables 2 and 3. The siRNA-1 of each gene was an equimolar mixture of two kinds. 25 3956219_1 (GHMatters) P79759.AU.1 -59 [0130] Table 2 Gene Symbol siRNA Name Position Sequence SEQ ID No. UBE2S siRNA-1 44-64 CCGGCCGGCCGCAGCCAUGAA 27 146-166 UGGCAUCAAGGUCUUUCCCAA 28 siRNA-2 473-491 GGAGAACUACGAGGAGUAU 29 siRNA-3 659-677 UGGCGAGCGCGAUAAGAAG 30 RFC4 siRNA-1 897-917 AGGGAAUAGCUUAUCUUGUUA 31 189-209 CUGCACGAGAAGCCAGGCUAA 32 siRNA-2 745-763 CCGAUUCUGUCUUAUCUGU 33 siRNA-3 1023-1041 GGGUAAUACCAGCUGAGAA 34 PTGES2 siRNA-1 2003-2023 CUGGGACAUGUUUGCAAUAAA 35 1105-1125 CUGGCUCAUGCUCAACGAGAA 36 siRNA-2 943-961 AGGAGAAAGCUCGCAACAA 37 siRNA-3 1086-1104 CCGAGUUCGGCAAUAAGUA 38 MAF1 siRNA-1 1538-1558 CAGCUGGACCGCAGAGUUUAU 39 1031-1051 UAGCCUCUGGUCCUUCAACUA 40 siRNA-2 604-622 ACGACAAACACAUGUUCAA 41 5 3956219_1 (GHMatters) P79759.AU.1 -60 [0131] Table 3 siRNA-3 856-874 GCCUUAGCUGGGUGGUGAA 42 ACVR2B siRNA-1 626-646 CAGCUCAUGAAUGACUUUGUA 43 208-228 CACCAUCGAGCUCGUGAAGAA 44 siRNA-2 684-702 GGCAGAGUGAACGGGAGAU 45 siRNA-3 840-858 GGAACAUCAUCACAUGGAA 46 FA 119A siRNA-1 754-774 AAGGUUCACUACGAUCCUGAA 47 1068-1088 UCGAUUUAUGCUAUUUGUGUA 48 siRNA-2 201-219 GGAAUUUGGGUUGCAGAAA 49 siRNA-3 810-828 CCAGAAGGAGGACUUAUAA 50 LTB4DH siRNA-1 775-795 CACUGUUAUCGGCCAGAUGAA 51 658-678 UGGAUUUGAUGUCGUCUUUAA 52 siRNA-2 263-281 GCCAAAAGAUUGAAGGAAG 53 siRNA-3 725-743 CCUGAUGGUUAUGAUUGUU 54 DP2 siRNA-1 145-165 CAGCAUGUCAUCCACAAGUAU 55 84-104 UAGCCUGAUCAUCUUCACCUA 56 siRNA-2 116-134 GGGUGAUUCUCUUGCCAUU 57 siRNA-3 224-242 UGUUUGUGGGACUGUUCAU 58 SEPT siRNA-1 870-890 CAGACUCUCGUCCUCACCGAA 59 794-814 CUGAAUGACGUUACACCCUCA 60 siRNA-2 161-179 GGGCGAGGUUUUCCAGAAU 61 siRNA-3 179-197 UCACUUUGAACCUGGCGUU 62 PSWA3 siRNA-1 853-873 CCAGUCCAAUGUAACUAUUUA 63 686-706 CUCAGCUGGGUUGGUGAAUUA 64 siRNA-2 291-309 UGGCAGAUGCUCGUUCUUU 65 siRNA-3 512-530 GGUGUUUCAUACGGUUAUU 66 CHCHD3 siRNA-1 546-566 CAGGAUGCAUUCUACAAAGAA 67 1450-1470 CUGGAAUAAUGUUUAUGAUUA 68 siRNA-2 374-392 CGAAGAUCAGAAACGACUA 69 siRNA-3 522-540 GAGAAAGACCGAGUGCUAA 70 LS3 siRNA-1 540-560 UCCAAUAAAUAUGACCACCAA 71 37-57 ACGACGUAGACCAGCAACAAA 72 siRNA-2 39-57 GACGUAGACCAGCAACAAA 73 siRNA-3 261-279 ACGAAACGGAAUAUUCCAA 74 GTSE1 siRNA-2 1082-1100 GGGCAAAGCUAAAUCAAGU 75 siRNA-3 2116-2134 UGACAAACACUCCAGACAU 76 [0132] 5 (2) Culture of human cancer cell strains The three kinds of cancer cell strains (HeLa: uterine cervix cancer, KYSE150: esophagus cancer, and HCC50: colon 3956219_1 (GHMatters) P79759.AU.1 -61 cancer) were cultured under the following conditions. HeLa was cultured in a DMEM culture medium (Nacalai Tesque Inc.) containing 10% fetal bovine serum (Sigma Corporation) and gentamycin (Sigma Corporation). KYSE150 and HCC50 were 5 cultured in RPMI 1640 culture media (Nacalai Tesque Inc.) containing 10% Fetal Bovine Serum and gentamycin. [0133] (3) Gene introduction of immortalization-determining gene sequence specific siRNA into cancer cell strain 10 On the day before the transfection, cancer cells previously cultured were isolated using trypsin. After being suspended in the culture medium detailed in (2) above, HeLa =1.2 x 104, KYSE150 = 2 x 104, and HCC50 = 1.5 x 104 were seeded for each well of a 24-well plate. On the day of 15 transfection, the media were replaced with serum-free media Opti-MEM (Invitrogen), and the siRNA shown in Table 2 and 3 were subjected to transfection using Oligofectamine (Invitrogen) or Lipofectamine 2000 (Invitrogen). The concentration of siRNA upon transfection was 40 nM per well. 20 A control (non-silencing) siRNA (Qiagen) was used as a negative control. [0134] (4) Assay of the suppression of relative mRNA expression of immortalization-determining gene 25 One day after the transfection detailed in (3), total RNA was extracted from each cancer cell strain using RNeasy Mini (Qiagen) according to the instruction book. Using a QuantiTect probe RT-PCR (Qiagen) and an immortalization determining gene sequence specific TaqMan probe (ABI), 30 quantitative RT-PCR (ABI PRISM 7000 sequence detection system (produced by ABI) was used) was performed under the following conditions. i) 500C, 30 minutes, 3956219_1 (GHMatters) P79759.AU.1 -62 ii) 950C, 15 minutes, iii) 940C, 15 seconds - 600C, 1 minutes x 35 to 45 cycles. [0135] Using B-actin as an internal standard, the expression 5 amount was digitalized based on each amplification curve. As a control, the value of a cell into which NS-sequence siRNA was introduced was used. Measurement of the relative mRNA expression of the immortalization-determining gene was performed twice with the same target gene and the same cancer 10 cell strains under the same conditions. [0136] FIGS. 16 to 28 show the percentages of relative mRNA amounts of immortalization-determining genes in the cells to which each of siRNAs was introduced, when the immortalization 15 determining gene mRNA percentage in the control is assumed to be 100%. The measurements are shown as mRNA-1 and mRNA-2, respectively, in FIGS. 16 to 28. The suppression of mRNA expression by any one of siRNAs (siRNA-1 to siRNA-3) was observed in all target genes. 20 [0137] (5) Measurement of the proliferation of cancer cell strains The proliferation of cancer cell strains was measured using viable cell count measurement reagent SF (Nacalai Tesque Inc.). At 96 hours after the transfection detailed in (3), 10 25 pl of WST reagent was added to each well. After 3-hour incubation at 370C, absorbencies at 450 nm and 595 nm (reference wavelengths) were measured using a plate reader (Wallac ARVO MX1420 Multilabel Counter: produced by Perkin Elmer). According to: absorbency at 450 nm - absorbency at 30 595 nm - absorbency at BG (only culture medium), the data was digitalized, and a mean value of three wells was found. Then, the value was shown as a percentage when the percentage of NS sequence siRNA introduction cell is assumed to be 100%. 3956219_1 (GHMatters) P79759.AU.1 -63 Measurement of proliferation of cancer cell strains was performed twice with the same target gene and same cancer cell strains under the same conditions. [0138] 5 The respective cell counts upon siRNA introduction are shown as MTT-1 and MTT-2, respectively, in FIGS. 16 to 28, when the percentage of cell count upon the NS sequence siRNA introduction is assumed to be 100%. In all target genes, the suppression of proliferation by any one of the siRNAs (siRNA-1 10 to siRNA-3) was seen in three kinds of cancer cells, indicating that those thirteen kinds of immortalization determining genes can be regarded as being target molecules to attain universal suppression of immortalized cancer cell proliferation. 15 [0139] The discrimination of immortalized cancer cells from mortal cancer cells has significance in functioning as a malum marker, as well as in contributing to remedy development. General cancer diagnosis is based on pathological findings, 20 with which the diagnosis of differentiation, atypism, etc., is also possible. However, general pathologic assays do not allow judgment as to whether the cells are immortalized, in other words, whether the cells have infinite lives. Human telomerase activation has attracted attention to date as an 25 immortalization marker. However, as shown above, telomerase activation has also been seen in some healthy cells; therefore, the new idea that telomerase activation does not always immediately immortalize cells has become knowledge. Further, since the telomerase expression amount is very low, even 30 though immune system staining was established, only a few laboratories have reported their achievements (Hiyama E et al., Neoplasia 3: 17-26, 2001) . The use of the marker of the present invention to detect the expression of an 3956219_1 (GHMatters) P79759.AU.1 -64 immortalization-determining gene allows immortalized cancer cells to be discriminated from finite life cells. Such discrimination was not possible by general conventional pathological diagnosis. The present invention thus has great 5 potential as a clinical application useful for early diagnosis, new treatment options, prognostification, and the like. BRIEF DESCRIPTION OF DRAWINGS 10 [140] FIG. 1 is a schematic view illustrating a mechanism of human cell canceration and immortalization. FIG. 2 is a schematic view illustrating a target gene extraction process according to the present invention. 15 FIG. 3 is a graph showing expression levels of UBE2S gene in the various immortalized cancer cells, using an oligo array. FIG. 4 is a graph showing expression levels of RFC4 gene in the various immortalized cancer cells, using an oligo array. FIG. 5 is a graph showing expression levels of PTGES2 gene in 20 the various immortalized cancer cells, using an oligo array. FIG. 6 is a graph showing expression levels of MAF1 gene in the various immortalized cancer cells, using an oligo array. FIG. 7 is a graph showing expression levels of ACVR2B gene in the various immortalized cancer cells, using an oligo array. 25 FIG. 8 is a graph showing expression levels of FAM119A gene in the various immortalized cancer cells, using an oligo array. FIG. 9 is a graph showing expression levels of LTB4DH gene in the various immortalized cancer cells, using an oligo array. FIG. 10 is a graph showing expression levels of DPM2 gene in 30 the various immortalized cancer cells, using an oligo array. FIG. 11 is a graph showing expression levels of SEPX1 gene in the various immortalized cancer cells, using an oligo array. FIG. 12 is a graph showing expression levels of PSMA3 gene in 3956219_1 (GHMatters) P79759.AU.1 -65 the various immortalized cancer cells, using an oligo array. FIG. 13 is a graph showing expression levels of CHCHD3 gene in the various immortalized cancer cells, using an oligo array. FIG. 14 is a graph showing expression levels of LSM3 gene in 5 the various immortalized cancer cells, using an oligo array. FIG. 15 is a graph showing expression levels of GTSE1 gene in the various immortalized cancer cells, using an oligo array. FIG. 16 is a graph showing an effect of expression suppression of UBE2S gene and suppression of cell proliferation given by 10 siRNA in cancer cell strains (Example 2). FIG. 17 is a graph showing an effect of expression suppression of RFC4 gene and suppression of cell proliferation given by siRNA in cancer cell strains (Example 2). FIG. 18 is a graph showing an effect of expression suppression 15 of PTGES2 gene and suppression of cell proliferation given by siRNA in cancer cell strains (Example 2). FIG. 19 is a graph showing an effect of expression suppression of MAF1 gene and suppression of cell proliferation given by siRNA in cancer cell strains (Example 2). 20 FIG. 20 is a graph showing an effect of expression suppression of ACVR2B gene and suppression of cell proliferation given by siRNA in cancer cell strains (Example 2). FIG. 21 is a graph showing an effect of expression suppression of FAM119A gene and suppression of cell proliferation given by 25 siRNA in cancer cell strains (Example 2). FIG. 22 is a graph showing an effect of expression suppression of LTB4DH gene and suppression of cell proliferation given by siRNA in cancer cell strains (Example 2). FIG. 23 is a graph showing an effect of expression suppression 30 of DPM2 gene and suppression of cell proliferation given by siRNA in cancer cell strains (Example 2). FIG. 24 is a graph showing an effect of expression suppression of SEPX1 gene and suppression of cell proliferation given by 3956219_1 (GHMatters) P79759.AU.1 -66 siRNA in cancer cell strains (Example 2). FIG. 25 is a graph showing an effect of expression suppression of PSMA3 gene and suppression of cell proliferation given by siRNA in cancer cell strains (Example 2). 5 FIG. 26 is a graph showing an effect of expression suppression of CHCHD3 gene and suppression of cell proliferation given by siRNA in cancer cell strains (Example 2). FIG. 27 is a graph showing an effect of expression suppression of LSM3 gene and suppression of cell proliferation given by 10 siRNA in cancer cell strains (Example 2). FIG. 28 is a graph showing an effect of expression suppression of GTSE1 gene and suppression of cell proliferation given by siRNA in cancer cell strains (Example 2). 15 SEQUENCE LISTING FREE TEXT [0141] SEQ ID No.27 represents the base sequence of the sense strand of siRNA-1 (44-64), of the UBE2S gene. SEQ ID No.28 represents the base sequence of the sense strand 20 of siRNA-1 (146-166), of the UBE2S gene. SEQ ID No.29 represents the base sequence of the sense strand of siRNA-2, of the UBE2S gene. SEQ ID No.30 represents the base sequence of the sense strand of siRNA-3, of the UBE2S gene. 25 SEQ ID No.31 represents the base sequence of the sense strand of siRNA-1 (897-917), of the RFC4 gene. SEQ ID No.32 represents the base sequence of the sense strand of siRNA-1 (189-209), of the RFC4 gene. SEQ ID No.33 represents the base sequence of the sense strand 30 of siRNA-2, of the the RFC4 gene. SEQ ID No.34 represents the base sequence of the sense strand of siRNA-3, of the RFC4 gene. SEQ ID No.35 represents the base sequence of the sense strand 3956219_1 (GHMatters) P79759.AU.1 -67 of siRNA-1 (2003-2023), of the PTGES2 gene. SEQ ID No.36 represents the base sequence of the sense strand of siRNA-1 (1105-1125), of the PTGES2 gene. SEQ ID No.37 represents the base sequence of the sense strand 5 of siRNA-2, of the PTGES2 gene. SEQ ID No.38 represents the base sequence of the sense strand of siRNA-3, of the PTGES2 gene. SEQ ID No.39 represents the base sequence of the sense strand of siRNA-1 (1538-1558), of the MAF1 gene. 10 SEQ ID No.40 represents the base sequence of the sense strand of siRNA-1 (1031-1051), of the MAF1 gene. SEQ ID No.41 represents the base sequence of the sense strand of siRNA-2, of MAF1 gene. SEQ ID No.42 represents the base sequence of the sense strand 15 of siRNA-3, of the MAF1 gene. SEQ ID No.43 represents the base sequence of the sense strand of siRNA-1 (626-646), of the ACVR2B gene. SEQ ID No.44 represents the base sequence of the sense strand of siRNA-1 (208-228), of the ACVR2B gene. 20 SEQ ID No.45 represents the base sequence of the sense strand of siRNA-2, of the ACVR2B gene. SEQ ID No.46 represents the base sequence of the sense strand of siRNA-3, of the ACVR2B gene. SEQ ID No.47 represents the base sequence of the sense strand 25 of siRNA-1(754-774), of the FAM119A gene. SEQ ID No.48 represents the base sequence of the sense strand of siRNA-1(1068-1088), of the FAM119A gene. SEQ ID No.49 represents the base sequence of the sense strand of siRNA-2, of the FAM119A gene. 30 SEQ ID No.50 represents the base sequence of the sense strand of siRNA-3, of the FAM119A gene. SEQ ID No.51 represents the base sequence of the sense strand of siRNA-1(775-795), of the LTB4DH gene. 3956219_1 (GHMatters) P79759.AU.1 -68 SEQ ID No.52 represents the base sequence of the sense strand of siRNA-1(658-678), of the LTB4DH gene. SEQ ID No.53 represents the base sequence of the sense strand of siRNA-2, of the LTB4DH gene. 5 SEQ ID No.54 represents the base sequence of the sense strand of siRNA-3, of the LTB4DH gene. SEQ ID No.55 represents the base sequence of the sense strand of siRNA-1(145-165), of the DPM2 gene. SEQ ID No.56 represents the base sequence of the sense strand 10 of siRNA-1(84-104), of the DPM2 gene. SEQ ID No.57 represents the base sequence of the sense strand of siRNA-2, of the DPM2 gene. SEQ ID No.58 represents the base sequence of the sense strand of siRNA-3, of the DPM2 gene. 15 SEQ ID No.59 represents the base sequence of the sense strand of siRNA-1(870-890), of the SEPX1 gene. SEQ ID No.60 represents the base sequence of the sense strand of siRNA-1(794-814), of the SEPX1 gene. SEQ ID No.61 represents the base sequence of the sense strand 20 of siRNA-2, of the SEPX1 gene. SEQ ID No.62 represents the base sequence of the sense strand of siRNA-3, of the SEPX1 gene. SEQ ID No.63 represents the base sequence of the sense strand of siRNA-1(853-873), of the PSMA3 gene. 25 SEQ ID No.64 represents the base sequence of the sense strand of siRNA-1(686-706), of the PSMA3 gene. SEQ ID No.65 represents the base sequence of the sense strand of siRNA-2, of the PSMA3 gene. SEQ ID No.66 represents the base sequence of the sense strand 30 of siRNA-3, of the PSMA3 gene. SEQ ID No.67 represents the base sequence of the sense strand of siRNA-1(546-566), of the CHCHD3 gene. SEQ ID No.68 represents the base sequence of the sense strand 3956219_1 (GHMatters) P79759.AU.1 -69 of siRNA-1(1450-1470), of the CHCHD3 gene. SEQ ID No.69 represents the base sequence of the sense strand of siRNA-2, of the CHCHD3 gene. SEQ ID No.70 represents the base sequence of the sense strand 5 of siRNA-3, of the CHCHD3 gene. SEQ ID No.71 represents the base sequence of the sense strand of siRNA-1(540-560), of the LSM3 gene. SEQ ID No.72 represents the base sequence of the sense strand of siRNA-1(37-57), of the LSM3 gene. 10 SEQ ID No.73 represents the base sequence of the sense strand of siRNA-2, of the LSM3 gene. SEQ ID No.74 represents the base sequence of the sense strand of siRNA-3, of the LSM3 gene. SEQ ID No.75 represents the base sequence of the sense strand 15 of siRNA-2, of the GTSE1 gene. SEQ ID No.76 represents the base sequence of the sense strand of siRNA-3, of the GTSE1 gene. 3956219_1 (GHMatters) P79759.AU.1
Claims (15)
1. A marker gene for determining cancer cell immortalization, the marker gene comprising a polynucleotide having a base sequence of at least 15 bases that specifically hybridizes with a continuous base sequence of at least 15 bases within any one of base sequences represented by SEQ ID Nos.1 to 13.
2. The marker gene according to claim 1, wherein the marker gene is a probe or primer.
3. A method for determining an immortalized cancer cell, comprising the steps of: (1) bonding the marker gene according to claim 1 or 2 with RNA prepared from a biological sample that is extracted from a test subject and that may contain a cancer cell, or a derivative of the RNA; (2) measuring an amount of the RNA or the derivative thereof bonded with the marker gene, using the marker gene as an index; and (3) comparing the amount of RNA or the derivative thereof found in Step (2) (generically referred to as "an RNA amount", hereinafter) with an amount (generically referred to as "a comparative RNA amount", hereinafter) of a corresponding RNA or a derivative thereof in a non-immortalized healthy or cancer cell.
4. The method for determining an immortalized cancer cell according to claim 3, further comprising the step of: (4) determining that the cancer cell of the test subject is immortalized when the RNA amount found in Step (2) is higher than the comparative RNA amount, and determining that 3956219_1 (GHMatters) P79759.AU.1 -71 the cancer cell of the test subject is not immortalized when the RNA amount found in Step (2) is not higher than the comparative RNA amount.
5. An antibody for recognizing a polypeptide having any one of amino acid sequences represented by SEQ ID Nos.14 to 26.
6. A method for determining an immortalized cancer cell, comprising the step of: (1') bonding a protein-containing fraction containing a polypeptide prepared from a biological sample that is extracted from a test subject and that may contain a cancer cell with the antibody according to claim 5; (2') measuring the amount of the polypeptide that is bonded with the antibody, using the antibody as an index; and (3') comparing the amount (generically referred to as "a polypeptide amount", hereinafter) of the polypeptide found in Step (2') with the amount (generically referred to as "a comparative polypeptide amount", hereinafter) of a corresponding polypeptide in a non-immortalized healthy or cancer cell.
7. The method for determining an immortalized cancer cell according to claim 6, further comprising the step of: (4') determining that the cancer cell of the test subject is immortalized when the polypeptide amount found in Step (2') is higher than the comparative polypeptide amount, and determining that the cancer cell of the test subject is not immortalized when the polypeptide amount found in Step (2') is not higher than the comparative polypeptide amount.
8. An immortalized cancer cell determining reagent kit including at least one member selected from the group 3956219_1 (GHMatters) P79759.AU.1 -72 consisting of the marker gene according to claim 1 and the antibody according to claim 5.
9. A method for screening a substance for suppressing proliferation of immortalized cancer cells, comprising the steps of: (A) bringing a test material into contact with a cell that can express one of the immortalization-determining genes represented by SEQ ID Nos. 1 to 13; (B) measuring an expression amount of one of the immortalization-determining genes represented by SEQ ID Nos. 1 to 13 in the cell brought into contact with the test material; (C) comparing the expression amount of the immortalization-determining gene found in Step (B) with an expression amount (generically referred to as "a comparative expression amount", hereinafter) of an immortalization determining gene in a cell not in contact with the test material; and (D) selecting the test material as a candidate substance for suppressing proliferation of immortalized cancer cells when the expression amount found in Step (B) is lower than the comparative expression amount.
10. A method for screening a substance for suppressing proliferation of immortalized cancer cells, comprising the steps of: (A') bringing a test material into contact with a polypeptide having one of the amino acid sequences represented by SEQ ID Nos. 14 to 26; (B') measuring activity of the polypeptide having one of the amino acid sequences represented by SEQ ID Nos. 14 to 26 brought into contact with the test material; (C') determining the degree of the activity of the 3956219_1 (GHMatters) P79759.AU.1 -73 polypeptide found in Step (B' ) by comparing the activity of the polypeptide found in Step (B') with activity (generically referred to as "a comparative activity", hereinafter) of a polypeptide not in contact with the test material; and (D') selecting the test material as a candidate substance for suppressing proliferation of immortalized cancer cells when the activity of the polypeptide found in Step (B') is lower than the comparative activity.
11. An immortalized cancer cell growth inhibitor containing, as an active ingredient, a polynucleotide having a base sequence of at least 15 bases that specifically hybridizes with a continuous base sequence of at least 15 bases within any one of base sequences represented by SEQ ID Nos. 1 to 13.
12. The immortalized cancer cell growth inhibitor according to claim 11, wherein the polynucleotide has any one of base sequences represented by SEQ ID Nos. 27 to 39.
13. A method of anticancer treatment comprising the step of administering the immortalized cancer cell growth inhibitor according to claim 11 or 12 to cancer cells of a patient.
14. Use of a polynucleotide having a base sequence of at least 15 bases that specifically hybridizes with a continuous base sequence of at least 15 bases within any one of base sequences represented by SEQ ID Nos. 1 to 13, for producing an immortalized cancer cell growth inhibitor.
15. The use according to claim 14, wherein the polynucleotide has any one of base sequences represented by SEQ ID Nos. 27 to 39. 3956219_1 (GHMatters) P79759.AU.1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012268818A AU2012268818A1 (en) | 2006-06-09 | 2012-12-20 | Gene involved in immortalization of human cancer cell and use thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-161350 | 2006-06-09 | ||
AU2007255677A AU2007255677B2 (en) | 2006-06-09 | 2007-06-08 | Gene involved in immortalization of human cancer cell and use thereof |
AU2012268818A AU2012268818A1 (en) | 2006-06-09 | 2012-12-20 | Gene involved in immortalization of human cancer cell and use thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007255677A Division AU2007255677B2 (en) | 2006-06-09 | 2007-06-08 | Gene involved in immortalization of human cancer cell and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2012268818A1 true AU2012268818A1 (en) | 2013-01-17 |
Family
ID=47560975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2012268818A Abandoned AU2012268818A1 (en) | 2006-06-09 | 2012-12-20 | Gene involved in immortalization of human cancer cell and use thereof |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2012268818A1 (en) |
-
2012
- 2012-12-20 AU AU2012268818A patent/AU2012268818A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9347101B2 (en) | Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer | |
US8329408B2 (en) | Methods for prognosis and monitoring cancer therapy | |
US20100105051A1 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
EP2094866B1 (en) | Diagnosis and treatment of breast cancer | |
CA2637369A1 (en) | Gene expression profiles and methods of use | |
WO2009007958A2 (en) | Compositions, methods and kits for the diagnosis of carriers of mutations in the brca1 and brca2 genes and early diagnosis of cancerous disorders associated with mutations in brca1 and brca2 genes | |
US20110294686A1 (en) | Egfr inhibitor therapy responsiveness | |
JP2018525034A (en) | Methods for providing tumor-specific T cells | |
CA2654978C (en) | Gene involved in immortalization of human cancer cell and use thereof | |
US7445892B2 (en) | Method of testing anticancer agent-sensitivity of tumor cells | |
AU2012268818A1 (en) | Gene involved in immortalization of human cancer cell and use thereof | |
WO2008098086A2 (en) | A gene expression profile that predicts ovarian cancer subject response to chemotherapy | |
JP2007175023A (en) | Composition and method for predicting prognosis and metastasis risk of cancer patient after operation | |
Li et al. | Mitogen stimulation activates different signaling pathways in early-and late-divided T cells as revealed by DNA microarray analysis | |
AU2011213720B2 (en) | Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer | |
Kenny | Analysis of messenger RNAs detectable in medium conditioned by tumour cells in serum from breast cancer patients | |
JP2011072231A (en) | Method for detecting endoderm cell, intestinal tract cell or pancreatic cell |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |